

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 May 2005 (12.05.2005)

PCT

(10) International Publication Number
WO 2005/043153 A1

- (51) International Patent Classification⁷: **G01N 33/00**, 21/00, 33/48, 33/53
- (21) International Application Number: PCT/US2004/035550
- (22) International Filing Date: 27 October 2004 (27.10.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/515,803 27 October 2003 (27.10.2003) US
- (71) Applicant and
(72) Inventor: **MEYER, Donald, W.** [US/US]; W686 Hwy. CW, Ixonia, WI 53036 (US).
- (72) Inventor; and
(75) Inventor/Applicant (for US only): **O'ROURKE, Katherine, I.** [US/US]; 1020 NW El Dorado, Pullman, WA 99163 (US).
- (74) Agents: **HOLLAND, Antonia, M.** et al.; Reinhart Boerner Van Deuren s.c., 1000 North Water Street, Suite 2100, Milwaukee, WI 53202 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2005/043153 A1

(54) Title: TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY DETECTION IN CERVIDS, SHEEP AND GOATS

(57) Abstract: A method for diagnosing scrapie in sheep or goats and chronic wasting disease in deer or elk is provided including detecting spectral changes between disease-positive samples and disease-negative samples providing a calibration model for use in classifying unknown samples as disease-positive or disease-negative.

TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
DETECTION IN CERVIDS, SHEEP AND GOATS

5 **Background of the Invention.**

Field of the Invention - The present invention relates to methods for detecting a change in spectral response between normal and diseased tissue and/or fluid samples as an indication of chronic wasting disease and/or scrapie, and more particularly, to a method of identifying a transmissible spongiform encephalopathy infection in a deer, elk, sheep or goat subject by comparing spectral data obtained from a sample taken from the cervid, sheep or goat subject to a calibration model including spectral data obtained from known TSE-normal and TSE-diseased samples obtained from the same species as the subject.

Transmissible spongiform encephalopathies (TSEs), also known as prion diseases, are a family of contagious, degenerative neurological diseases found in humans and animals. A TSE infects the central nervous system of a host species and eventually attacks the brain of the host species. TSEs have a long incubation period, and once infected, a host species may not exhibit clinical symptoms for years. Clinical symptoms of TSEs can include emaciation, loss of bodily condition, loss of coordination and movement, excessive salivation, and/or loss of bodily functions. While the clinical symptoms of each specific transmissible spongiform encephalopathy (TSE) may vary somewhat from species to species, TSEs always cause death in infected victims.

TSEs are characterized by tiny holes or lesions in the brain that give the brain a sponge-like appearance and are associated with the aggregation in the brain of prions, an abnormal form of a naturally occurring, membrane protein called a prion protein (PrP). Normal prion protein molecules, designated as PrP or PrP^c (cellular), are predominantly found on the surface of neuronal cells and in spinal fluid as well as on the surface of certain other non-neuronal cell types such as lymphoreticular tissue. The normal PrP^c is sensitive to digestion with specific enzymes.

Disease-associated prions are defined as small, proteinaceous infectious particles that resist inactivation by procedures that modify nucleic acids. These

infectious prions, designated PrP^{res} (protease resistant protein), are characterized as abnormal, insoluble isoforms of normal mammalian PrP^c.

Normal PrP^c and infectious PrP^{res} share the same amino acid sequence and have almost identical molecular weights of 33 to 35 kd (6033858), but differ
5 from each other in their secondary structure. Normal prion proteins contain a predominantly alpha helix structure and contain almost no beta sheet structure. It is believed that the difference between normal PrP^c and infectious PrP^{res} is conformational, with infectious PrP^{res} containing a significantly higher beta-sheet content than normal PrP^c. The normal prion protein's usual function is unknown,
10 but its shape can be converted into the abnormal, beta-sheet rich disease-associated form. Once the abnormal prions are present, it is suggested that the abnormal prion protein spreads in a chain reaction by converting normal prion molecules into the abnormal form, i.e. converting PrP^c to PrP^{res}.

The pre-clinical phase of a TSE is the long incubation period after
15 infection with PrP^{res} in which the species exhibits no external clinical symptoms of the disease. However, it is known that the presence of PrP^{res}, or a precursor thereof, can be detected in the lymphoreticular system and in lymphoreticular tissues such as the tonsils, lymph nodes, eyes, spleen, or blood in mammalian species susceptible to TSEs. For example, because infectious prions, PrP^{res}, are
20 protease resistant, it is suggested that prions accumulate in the lymph system or nervous system of an animal species, in addition to the brains of infected the host, where they aggregate into distinctive filaments or plaques on the surface of the cell membrane.

Prions are transmitted from one host to another; however, they do not
25 exhibit many other features of traditional infective agents, such as bacteria, viruses, or fungi. As such, prions are referred to as infectious "agents" of disease. How a prion moves from species to species is somewhat unclear; however, it is known that a TSE can be transmitted from animal to animal contact, and that animals exposed to a TSE contaminated environment, infected tissue, body
30 fluids, infected carcasses, or contaminated medical instruments may also become infected. Once the infectious agent enters the brain of the host, it can lie dormant for several years, but when it is activated, the abnormal prion molecules kill brain

cells leaving large areas of spongy holes in the brain, and leaving large clumps of abnormal prion protein in the brain. Once the abnormal prion is activated, the disease can run its course in less than a year, causing death. Further, it has also been discovered that routine sterilization procedures, such as boiling or
5 irradiation, do not prevent transmission of TSEs. Further, cleaning chemicals that one would use to disinfect surfaces for bacteria or viruses such as Lysol, or Betadine, are not effective in destroying the infectious capability of the prions.

Scrapie, a disease that has been well known for several centuries, is the infective TSE found in goats or sheep. Scrapie is thought to be spread from the
10 ewe to her offspring and to other lambs through contact with the placenta and placental fluids. In addition, it is believed that some sheep carry a genetic predisposition for susceptibility to a scrapie infection. Scrapie infected flocks of sheep or goats that contain a high percentage of susceptible animals can experience significant losses. As the number of infected animals increases, the
15 age at onset of clinical signs decreases, making these flocks economically unviable. In addition, the presence of scrapie in the United States prevents the export of breeding stock, semen, and embryos to many other countries.

Chronic wasting disease (CWD) is a TSE found in free ranging and captive mule deer, white tailed deer and elk across North America. CWD is of
20 particular concern because the presence of CWD across the United States and Canada is growing. In addition, CWD is of particular concern in the United States where deer hunting is a traditional part of recreational sporting and tourism in several states where infected deer and elk have been discovered. In addition, CWD has affected wildlife industries as well as domestic and international
25 markets for farmed cervids and cervid products.

Moreover, it has been suggested that food products containing TSE infected tissue may cause cross-species forms of a transmissible spongiform encephalopathy disease. For example, it is believed that in the 1980's, feed contaminated with scrapie-infected sheep tissue and/or sheep by-products was fed
30 to cattle causing infection. It is unknown whether humans can be infected with a TSE by ingesting CWD infected meat from deer or elk. However, the occurrence

of new variations of TSEs and the spread of CWD in the United States has emphasized the need for a reliable and efficient test for the disease.

Current Methods of Detection

5 Current diagnosis of Chronic wasting disease or scrapie involves several different methodologies.

 Postmortem microscopic or histological examination of brain tissue, especially the medulla oblongata at the obex, is still routinely performed as a method of confirming a CWD or scrapie case. However, such method requires
10 the expertise of laboratory technicians and is time consuming, and therefore, not a practical method of testing a large volume of tissue samples. In addition, microscopic examination of brain tissue detects lesions in the brain occurring only after the onset of the clinical disease, but is not used to detect early stages of infection with the disease.

15 The Western Blot assay test for the detection of CWD or scrapie relies on the differential sensitivity of the infectious prions, PrP^{res}, to protease K and thus, can be a quantitative measure of the presence of infectious prions. Tissue samples, for example, brain or lymph tissue, are first digested with protease K or an antibody that can discriminate between normal cellular PrP^c of the specific
20 host species and the protease resistant form PrP^{res}. The sample is denatured and diluted to an end point where PrP^{res} can no longer be detected in SDS PAGE gel. While Western Blot is considered a reliable, gold standard test for the detection of prion proteins, and therefore, a diagnosis for CWD, the Western Blot test is considered technically demanding, involves careful and inefficient preparation of
25 samples, and required the use of expensive and environmentally sensitive monoclonal antibodies. Accordingly, improper analytical techniques, instrumentation malfunctions, biased calculations, or inconsistent sample preparation techniques from technician to technician can result in errors in the test, and therefore, the possibility in error in test results. Because of these
30 difficulties and because Western Blot testing cannot be automated, it is not an appropriate test for the routine diagnosis, confirmation or screening of samples for a TSE in large populations of deer, elk, sheep or goat.

CWD testing is also performed by immunohistochemistry assay of formalin fixed tissues. Although IHC is a sensitive and specific diagnostic test, the assay requires careful collection and trimming of tissues, formalin fixation, processing and sectioning, IHC assay, and interpretation of results by a pathologist. The turnaround time is minimally measured in days and laboratory capacity is limited. In addition, tissue preparation is lengthy and subject to operator error. As with the Western Blot assay, use of expensive PrP^{res} specific monoclonal antibodies is a further disadvantage to implementing this type of testing in a large-scale application. Further, the nature of IHC testing makes diagnosis of CWD at the early stages of the disease subject to operator error or inconsistency from operator to operator.

Newer methods include, for example, the tonsillar biopsy method, in which tonsil tissue is collected from live or deceased deer or elk and tested using either of the aforementioned assays. This method is advantageous because it can be performed on live or quarantined deer, and because it can be used to detect the presence of CWD at an earlier stage of infectivity. However, the method involves racking, capturing, sedating and sampling individual deer and/or elk in infected areas or zones, making widespread application of the method expensive and time consuming to execute.

With respect to scrapie, commercial testing to determine the genetic makeup of sheep, with respect to the mutation of the prion gene, at codons 136 and 171, is available in the United States. Indeed, genetic testing for susceptibility is currently being practiced by many breeders. However, such genetic testing can be very costly and time consuming.

IR spectroscopy can be used to measure the absorbance/reflectance of infrared light in a sample. Specific absorbance peaks can be correlated to the presence of specific functional groups, chemical bonds and/or structural features of a compound in the sample, including water, proteins, or lipids. The absorbance patterns of samples can be compared to a reference (calibration) set to identify peaks specifically associated with a group, bond or structural feature of interest. IR analysis, alone or in conjunction with a Fourier transform function (FTIR), is a standard tool in some prion research laboratories, in which the difference in

protein conformation between the normal cellular prion protein and the disease-associated prion were detected. Diagnostic use of the method has been investigated in a hamster model of scrapie. However, application of the technique to naturally occurring chronic wasting disease or scrapie has not been
5 described. Moreover, these applications utilize FTIR microscopy in conjunction with an FTIR spectroscopy instrument, requiring time consuming sample preparation, long scanning times and significant operator training. Further, in conjunction with the prior, the cost of FTIR microscopy equipment and required accessories discourages routine, widespread use of these methods in the diagnosis
10 of CWD or scrapie.

Brief Description of the Drawings.

Figure 1A is a schematic structure of a lymph node, identifying the cortex and paracortex regions and the primary and secondary follicles contained therein
15 and illustrating a preferred method of sectioning a lymph node to expose the cortex or paracortex without exposing medulla sections;

Figure 1B is a schematic structure of a sheep brain and brain stem, identifying the obex portions utilized in the present invention;

Figure 2 illustrates the absorbance spectra (4000 cm^{-1} to 500 cm^{-1}) from
20 for a lymph tissue sample taken from a known positive (CWD-infected) white tailed deer subject;

Figure 3 illustrates the absorbance spectra (4000 cm^{-1} to 500 cm^{-1}) from
for a lymph tissue sample taken from a known negative (disease free) white tailed deer subject;

25 Figure 4 is a scatter plot of the Mahalanobis distances for each calibration sample within the calibration set of Example 1, illustrating two distinct clusters of tissue samples, corresponding to a "positive" cluster of tissue samples and a "negative" cluster of tissue samples;

Figures 5A and 5B are calibration results tables of the cross-validated
30 calibration data of Example 1 and plotted in Fig. 4;

Figure 6 is a scatter plot of the Mahalanobis distances for each validation sample, in addition to the calibration samples, in Example 1 demonstrating

alignment with either the "positive" cluster or "negative" cluster of the calibration data set;

Figures 7A and 7B are validation results tables of the validation set data of Example 1 and plotted in Fig. 6;

5 Figure 8 is a scatter plot of the Mahalanobis distances for each calibration sample within the calibration set of Example 2, illustrating two distinct clusters of tissue samples, corresponding to a "positive" cluster of tissue samples and a "negative" cluster of tissue samples;

10 Figure 9 is a scatter plot of the Mahalanobis distances for each validation sample, in addition to the calibration samples, in Example 2 demonstrating alignment with either the "positive" cluster or "negative" cluster of the calibration data set of Example 2;

15 Figure 10 is a scatter plot of the Mahalanobis distances for each calibration sample within the calibration set of Example 3, illustrating two distinct clusters of tissue samples, corresponding to a "scrapie positive" cluster of tissue samples and a "scrapie negative" cluster of tissue samples;

Figure 11 is a calibration results table of the cross-validated calibration data of Example 3 and plotted in Fig. 10;

20 Figure 12 is a scatter plot of the Mahalanobis distances for each validation sample in Example 3 demonstrating alignment with either the "scrapie positive" cluster or "scrapie negative" cluster of the calibration data set;

Figure 13 is a validation results table of the validation set data of Example 3 and plotted in Fig. 12;

25 Figure 14 is a scatter plot of the Mahalanobis distances for each calibration and validation sample in Example 4 demonstrating a "scrapie positive" cluster or "scrapie negative" cluster for whole blood samples;

Figure 15 is a results table presenting the calibration and validation results of Example 4 and plotted in Fig. 14;

30 Figure 16 is a scatter plot of the Mahalanobis distances for each calibration and validation sample in Example 5 demonstrating a "scrapie positive" cluster or "scrapie negative" cluster for blood serum samples;

Figure 17 is a results table presenting the calibration and validation results of Example 5 and plotted in Fig. 16;

Figure 18 is a results table presenting the calculated score for each of the samples in Example 5A;

5

Figure 19 is a scatter plot of the Mahalanobis distances for each calibration and validation sample in Example 6 demonstrating a "scrapie positive" cluster or "scrapie negative" cluster for blood plasma samples; and

Figure 20 is a results table presenting the calibration and validation results of Example 6 and plotted in Fig. 19.

10

Summary of the Invention.

In light of the forgoing, there is a need for an efficient, inexpensive and reliable method for detecting chronic wasting disease in cervids (deer and/or elk) or scrapie in sheep or goats, in a high throughput environment in order to increase the efficiency of surveillance and containment efforts. As described herein, any reference made to a transmissible spongiform encephalopathy (TSE) refers to chronic wasting disease (CWD) infections found in deer or elk and scrapie infections found in sheep or goats. In addition, reference to an animal "species" includes deer, elk, sheep and goats and encompasses all genotypical variations/breeds thereof.

Accordingly, it is an object of the present invention to use an IR spectroscopic method, such as Fourier transform infrared spectroscopy (FTIR), as a rapid test for detecting naturally occurring transmissible spongiform encephalopathy infections in live and/or postmortem deer, elk, sheep and/or goats, thereby overcoming various deficiencies and shortcomings of the prior art, including those outlined above. It is a further object of the invention to provide a calibrated spectrometric system for detecting spectral changes between TSE-positive (diseased) and TSE-negative (normal) untreated samples, thereby providing a means for diagnosing CWD in deer or elk and/or scrapie in sheep or goats. It is a related object of the present invention to provide a method for confirming a diagnosis of CWD and/or scrapie infection subsequently obtained using conventional testing methodologies.

Thus, it is a related object of the present invention to provide a method for diagnosing a TSE in any live or postmortem cervid, sheep or goat species that utilizes IR to detect spectral changes between naturally occurring TSE-positive and TSE-negative (fresh or previously frozen) lymph tissue, brain tissue and/or blood substantially untreated samples to provide a calibrated system and method for detecting such TSE in unknown lymph tissue, brain tissue or blood samples of the same species and type.

It is another object of the present invention to provide a primary analytical method for diagnosing a chronic wasting disease and/or scrapie infection that does not destroy the sample, nor requires technically difficult and time

consuming mechanical and/or chemical preparation of the sample before a diagnostic result can be obtained. Accordingly, it can be a further object of the present invention to provide a primary test for the diagnosis of CWD or scrapie, wherein a misdiagnosis of such TSE infection is minimized by eliminating
5 systematic and random errors that occur in sample preparation, testing, and interpreting the results of currently known methods. Ergo, it can be an object of the present invention to provide a more reliable and predictable method for diagnosing a CWD or scrapie infection.

It is therefore a further object of the present invention to minimize the
10 costs of analyzing samples for a TSE infection wherein there are no expensive chemicals or antibodies needed in sample preparation, the operators require no special training, and the instrumentation is inexpensive compared to traditional methods of detection. It is a related object of the present invention to reduce the time required to not only prepare the sample, but perform analysis of the sample
15 so that high-volume, rapid throughput testing of samples can be performed easily by governments and researchers. Thus, because there is no subjectivity in the analysis of the spectral information, operator fatigue will not affect the outcome of the analysis.

It will be understood by those skilled in the art that one or more aspects of
20 this invention can meet certain objectives, while one or more other aspects can meet certain other objectives. Each objective may not apply equally, in all instances, to every aspect of the present invention. As such, these objectives can be viewed in the alternative with respect to any one aspect of the present invention.

25 Other objects, features, benefits and advantages of the present invention will be apparent from the foregoing, in light of the summary and the examples and descriptions which follow, and will be readily apparent to those skilled in the art having knowledge of various prion detection systems, chronic wasting disease and/or scrapie diagnosis methods, conventional sample preparation techniques,
30 and subsequent application thereof. Such objects, features, benefits and advantages will be apparent from the above as taken in conjunction with the

accompanying examples, tables, graphs, data and all reasonable inferences to be drawn therefrom.

Without limitation to any particular theory or mode of operation, the spectrometric method described herein identifies one or more constituent groups, functional groups and/or structural features of a molecular compound or composition evidenced by one or more spectra from a diseased sample corresponding to either the presence of the diseased prion protein, PrP^{res}, in the diseased sample, or another chemical, molecular and/or structural alteration occurring within the sample as a precursor to the onset of the clinical disease. Thus, spectral differences between normal and diseased samples can be observed before the TSE induced lesions are observed in the sample. By developing a calibration model for deer, elk, sheep and/or goat animals, these spectral distinctions provide a method for differentially diagnosing a naturally occurring TSE in unknown samples from that species. The spectrometric method used may be absorption, reflectance, emission or transmission spectrometry. Preferably, absorption or reflectance spectra are obtained from a sample using Fourier transform infrared spectroscopy (FTIR) in order to provide a test wherein there is substantially constant pathlength through the sample, and therefore, more consistency from sample to sample and therefore, in the test results.

20

Sample Preparation

In a first embodiment of the present invention, and with reference to Examples 1 through 3, test samples are obtained from the lymphatic system of a cervid, sheep or goat animal. As illustrated in Fig. 1A, lymph tissue samples are obtained by sectioning a lymph node 50 to expose the cortex 52 or paracortex 54 regions of the node in order to preferably obtain a sample section that includes primarily primary 56 and/or secondary follicles 58, but which minimizes medullary tissue 60 within the sample. Preferably, retropharyngeal node tissue is obtained. It will be apparent to those skilled in the art that any lymphatic system tissue may be used in the present invention, including but not limited to, any lymph node, spleen, lymph nodules (tonsils), thymus, appendix (Peyer's patches) and/or small intestines.

30

Certain embodiments of the present invention utilize blood samples to practice the methods described herein. (Reference is made to Examples 4 through 6). Blood samples include not only whole blood, but also blood components such as plasma and blood serum. Blood components such as plasma or serum may be separated by conventional methods as are well known to those skilled in the art. Accordingly, the present invention provides a method for detecting chronic wasting disease or scrapie utilizing a blood sample obtained from a live animal subject.

Thus, consistent with the broader aspects of the present invention, other biological fluids known to those skilled in the art to contain PrP^{res} or another TSE-indicating molecular alteration may be utilized. As such, suitable samples can include tears, milk, saliva, semen, or sweat. Further, suitable samples may also include bodily waste such as urine, feces, or menstrual blood.

In other embodiments of the present invention, central nervous system tissues may be utilized. In particular, as illustrated in Fig. 1B, brain tissue, such as obex tissue and/or caudal medulla tissue of the cervid, sheep or goat may be obtained for use in the present invention, as it has been demonstrated that these tissues contain PrP^{res} or another molecular alteration indicative of a TSE infection. As such, spinal cord tissue and/or spinal fluid may also be used. Consistent with the broader aspects of the invention, suitable tissue samples include additional organ tissues, including but not limited to eye, pancreatic tissue, muscle tissue, tongue tissue, nerve cells and/or bone marrow. In particular, any cervid, sheep or goat tissue demonstrated to contain PrP^{res} or another TSE-indicating molecular alteration may be utilized in the methods of the present invention. As described herein, a "sample" refers to a tissue sample, blood and/or a biological fluid sample as previously described.

As described herein "untreated" samples include samples involving substantially no work-up (chemical, physical or mechanical manipulation) prior to testing. Untreated samples can include fresh and/or thawed samples and also include raw and/or unadulterated samples provided for testing involving substantially no sample preparation other than obtaining the proper amount of the sample. In particular, as distinguishable from the prior art, untreated samples are

not homogenized or mixed with water, subjected to enzyme action or chemically or physically extracted.

Preferably, samples are utilized untreated and are neither frozen, heated, nor dried prior to testing. However, raw, untreated samples may be frozen at
5 conventional storage temperatures, e.g. -35°C or -70°C , or as required by the particular laboratory or testing facility. Frozen samples are cut and/or thinly sectioned to expose a new surface to the spectrometric test instrumentation prior to testing.

In preparation for testing, thin sample sections of approximately about 1
10 cm x about 1 cm x about 0.2 cm in dimension are obtained from the animal species. Sample sections of up to about 3 cm x about 3 cm x about 0.5 cm may also be obtained, depending on the particular requirements of the spectrometric instrumentation and testing accessories employed in performing the methods of the present invention. Where biological fluids are used, samples from
15 approximately about 10 μl to about 1 ml are obtained from the subject. As will be readily apparent to those skilled in the art, sample size is dependent on not only specific test instrumentation but also on the availability of the sample and the need for further testing of the sample.

Any of the aforementioned sample types may be used to develop a
20 calibration model for a particular animal species and can include several different breeds/varieties of that species, including, but not limited to, a deer calibration model (including red deer, white-tailed deer, mule deer, etc.), an elk calibration model, a sheep calibration model (including Dorset, Merino, Cotswold, Suffolk etc.) or a goat calibration model (including Rock Alpine, Toggenburg, Saanen,
25 etc.) in order to classify unknown samples from the same type of animal species as TSE-positive or TSE-negative. In addition, a single calibration model can be developed for specific breeds of the same species of deer, elk, sheep or goats (e.g. a white-tailed deer calibration model/diagnostic test). Calibration models can also include models directed to a single gender. Thus, it will be apparent to those
30 skilled in the art that the present methodology is unlimited as to either animal genotype (deer, elk, sheep or goat) or strain of TSE.

The type of unknown sample tested using the methodology of the present

invention (e.g. lymph tissue, blood or brain tissue) is preferably the same type of sample used for developing the calibration model for the particular species. In addition, it is preferred that each sample used in a particular calibration model or used for a particular diagnostic test be stored at similar temperatures. For
5 example, calibration data sets developed with samples stored at about -70°C prior to testing should be used to test unknown samples stored at about -70°C . However, samples stored at, for instance, -35°C and fresh samples may be used to develop the same calibration model – which can be used to test unknown samples stored at -35°C and fresh samples.

10 The raw, untreated samples are placed directly on the optical bench and a complete scan of the sample is rapidly obtained. Because sample preparation is minimal, samples tested by the present method can be subsequently analyzed and/or confirmed by immunohistochemistry (IHC), Western Blot or another validated gold standard test for detecting CWD and/or scrapie.

15

Development of a Calibration Model.

To develop a calibration model, a calibration set of infrared absorption data (or alternatively reflectance data) is obtained from samples extracted from subjects that have previously been identified as TSE-positive or TSE-negative
20 (for CWD or scrapie). The infrared absorbance spectra for each of the known samples are obtained at wavenumbers from about 7400 cm^{-1} to about 350 cm^{-1} , preferably from about 4500 cm^{-1} to about 350 cm^{-1} , and more preferably from about 4000 cm^{-1} to about 500 cm^{-1} . Without limitation, a more discreet wavenumber range from about 1700 cm^{-1} to about 1600 cm^{-1} may also be used to
25 develop a calibration model – wherein such a wavenumber region includes at least a portion of the spectral changes observed between TSE-positive and TSE-negative samples. Thus, consistent with the broader aspects of the present invention, absorbance spectra may be obtained at any range of wavenumbers or wavelengths, or may be obtained in a more discrete range of wavenumbers or
30 wavelengths, depending on the type of sample, the spectrometric method used, and/or the particular TSE to be diagnosed.

The calibration/reference set of infrared absorption data can be prepared

from any number of reference samples, however, the calibration/reference data set will preferably include greater than about 10 reference samples.

Each sample in the calibration set can be scanned multiple times and co-added to increase the signal to noise ratio, thereby enhancing the spectral
5 absorbance features of the sample (that is, the spectral features correlated in the frequency/wavelength domain). For example, tissue samples may be scanned approximately about 64 times, while biological fluids may be scanned approximately about 16 to about 32 times. One skilled in the art will appreciate that a sample may be scanned as many times as necessary to sufficiently
10 distinguish/enhance the correlated spectral features from spectral noise (which shows no correlation in the frequency/wavelength domain). Generally, the more spectra included in the calibration set, the better chance there is of accounting for sample variations/impurities, instrument drifts and changes, and/or operator mistakes; thus, the test will be more sensitive. Irrespective of the number of
15 multiple scans collected for a given sample, it is contemplated by the present invention that complete scanning of a single sample (including multiple scans of the same sample) can be performed, preferably, in less than about one minute.

After each calibration/reference sample is scanned and the respective spectra collected, corresponding calibration models characteristic of a TSE-
20 positive sample and a TSE-negative sample are developed from the calibration spectral data. Fig. 2 is an example of raw spectral data for a lymph tissue sample taken from a known positive (CWD-infected) white tailed deer subject and Fig. 3 is an example of absorbance spectra for a lymph tissue sample taken from a known negative (disease free) white tailed deer subject.

25 Preferably, prior to performing any of the data analysis methods described herein, original spectra is converted to second derivatives to enhance spectral details, such as shoulders of IR bands and to minimize or eliminate baseline shifts. However, the original spectra and/or first derivatives can be used in the spectral analysis for development of the predictive model, as will be well known
30 to those skilled in the art. Data smoothing may be performed using a range of Savitzky-Golay algorithms or by weighted averaging the data using a set of weights that are a normalized Gaussian distribution. Further, any other data

smoothing technique known to those skilled in the art may be used.

It will also be readily apparent to those skilled in the art that the data may first be mean centered, linearized, or otherwise normalized before such data analysis. Normalization of spectra may also be required when the calibration
5 data/diagnostic test is transferred to a different spectrometric instrument (i.e. a different testing location), or where samples are tested on different spectrometric instruments. For example, Multiplicative Scatter Correction to account for pathlength variation can be performed prior to utilizing one of the data analysis methods referenced herein.

10 In order to reduce the amount of spectral data for analysis, the original spectra obtained for each of the known TSE-positive calibration samples are averaged and the original spectral obtained for each of the known TSE-negative samples are averaged. The average spectra for the TSE-positive samples and the average spectra for the TSE-negative samples are subtracted and/or the average
15 spectra are superimposed in a manner that highlights the wavenumber regions exhibiting the most prominent spectral distinctions between the average TSE-positive and the average TSE-negative spectra. These spectral regions are then selected for further analysis/discrimination between the spectra of TSE-positive and TSE-negative samples. Consistent with the broader aspects of the present
20 invention, data reduction can be performed on original (raw) spectra, first or second derivative spectra, data smoothed and/or normalized spectra.

In addition, it will be apparent to those skilled in the art that the entire spectral range of wavenumbers obtained during scanning of the calibration samples can be used in the methodology of the present invention, without
25 utilizing a data reduction technique, provided the data analysis method utilized is capable of sufficiently discriminating between TSE-positive and TSE-negative samples in the calibration set such that unknown TSE-positive and TSE-negative samples can be accurately diagnosed.

Preferably, the method utilizes principal component analysis (PCA) as a
30 chemometric method for breaking down spectroscopic data into its most basic variations. This type of multivariate technique analyzes entire regions of a spectrum and allows discrimination between the spectra of different groups of

samples. In particular, PCA data transformation converts a set of correlated spectral features/variables (the raw spectral data) into a compressed smaller set of uncorrelated variables. This transformation rotates the coordinate system, resulting in the alignment of information on a fewer number of axes than in the original spectral arrangement. This results in a compression of the variables by allowing those variables that are highly correlated with one another to be treated as a single entity. After using PCA, there will be a small set of uncorrelated variables representing most of the information that was in the original set of variables; however, the information will be easier to use in subsequent analytical models.

Consistent with the broader aspects of the invention, any mathematical data analysis technique, spectral data compression technique, predictive modeling method, and/or chemometric analysis method known to those skilled in the art can be used to identify spectral correlation corresponding to a TSE-positive and a TSE-negative disease state within the calibration data set, provided the data analysis technique is capable of sufficiently discriminating between TSE-positive and TSE-negative samples in the calibration set such that unknown samples can be accurately diagnosed. Such techniques can include but are not limited to, Partial Least Squares Regression (PLS), Principal Component Regression (PCR), Multiple Linear Regression (MLR) and Discriminant Analysis. It will at once be appreciated by those skilled in the art that any of the data smoothing, normalization, statistical methods and/or data analysis techniques described herein can be performed using a commercially-available computer software program. Such programs can include, but are not limited to OMNIC® (2002 Thermo Electron Corporation) including TQ Analyst® software (from Thermo Electron Corporation, Madison, WI, U.S.A.); or PLSplusIQ™ and GRAMS/AI™ (from Thermo Galactic, Salem, NH, U.S.A).

Accordingly, principal component analysis identifies patterns in the calibration/reference set spectra that contribute the most to the variation among that group, resulting in mathematical spectra (called loading vectors or principal components) which represent the most common variations to all the calibration data. The first principal component is constructed to account for as much

variability as possible; this often corresponds to the major visual differences among spectra as caused by light scatter, path length changes, or particle size differences. The second principal component is constructed to account for as much of the remaining variability as possible. This often corresponds to the largest absorbance band changes, such as moisture. Additional components will include variation in other bands. A discussion of the underlying theory and calculations of principal component analysis can be found, for example, in Fredericks, et al., *Applied Spectroscopy*, 39, 303 (1985); Aries, et al., *Spectroscopy*, 5, 41 (1990); and Haaland, et al., *Analytical Chemistry*, 60, 1193 (1988).

The amount of variability accounted for in each principal component depends on the specific TSE, the type of sample, and the number of samples in the calibration set. Each time a calibration set is developed, optimized or expanded, the number of principal components used for the predictive model can fluctuate, as needed, to account for variability approaching about 100%. Thus, in order to develop a sensitive calibration model, the number principal components used may account for as much variability in the calibration spectra as possible and/or as practical. Typically, about 2 to about 25 principal components will account for about 85% to greater than about 99.9% of the variance of the variables. However, up to about 50 or more principal components can be used, depending on the type of sample used and the variability thereof.

The principal components are then used to predict the disease-state of "unknown" samples. To do this, a set of scaling coefficients called principal component scores ("PC scores"), for each principal component, are calculated for each sample in the calibration set. When the PC scores are multiplied by the principal components, and the results are summed, the original spectra are reconstructed. By knowing the set of principal components, the PC scores will represent the spectra as accurately as the original spectral responses at all the wavelengths considered. Thus, scatter plots of the PC scores over the principal components can provide a means for visualizing and summarizing the spectral data.

In a first example of the present invention, principal component analysis

showed that the first ten (10) principal components accounted for about 98% of the total variance of the calibration tissue spectra. As illustrated in Fig. 4, a scatter plot of the calibration spectral data set after PCA transformation illustrates two distinct clusters of samples, a first cluster 100 corresponding to CWD-
5 positive samples (triangular data points) and a second cluster 102 corresponding to CWD-negative samples (square data points). Accordingly, the calibration data set is used, after PCA transformation, to differentially identify TSE-positive and TSE-negative samples by comparing the unknown sample's spectral PC scores to the PC scores determined from the spectral data of known samples in the
10 calibration set.

After all the calibration samples are scanned and the PC scores for each calibration sample in the calibration data set are calculated, the mean center PC scores are calculated for both the TSE-positive and TSE-negative cluster groupings. Alternatively, a mean centered spectra can be calculated for the entire
15 calibration data set by averaging the absorbance/reflectivity values of the calibration samples at each wavelength to determine a mean spectra for each of the TSE-positive and TSE-negative cluster groupings, and the mean centered PC scores can be calculated therefrom. The mean center PC scores will be unique to each specific cluster grouping.

20 Further, the calibration set can be cross-validated by calculating the Mahalanobis distances from each known sample in the calibration set to the mean center TSE-positive PC scores and the mean center TSE-negative PC scores of the remaining known samples in the calibration set (e.g. by rotating each cross-validated sample out of the calibration set and calculating the Mahalanobis
25 distances for that sample from the mean center TSE-positive PC scores and the mean center TSE-negative PC scores of the remaining known samples in the calibration set.) As well known to those skilled in the art, the Mahalanobis distance is used for determining the "similarity" of a sample to a reference set, for example, by comparing the unknown sample's PC scores to the mean center PC
30 scores of both the TSE-positive and the TSE-negative cluster groupings of the calibration data set.

To determine whether an unknown sample is TSE-positive or TSE-

negative, the unknown sample (or, alternatively, a validation sample previously identified as TSE-positive or TSE-negative) is first scanned to obtain the sample's spectral information. The PC scores of the unknown sample are then calculated. The Mahalanobis distances from both the mean center of the TSE-positive cluster
5 grouping and the TSE-negative cluster groupings for the particular unknown sample are calculated from the calculated PC scores for the unknown sample. If the Mahalanobis distance from the unknown sample's PC scores to the mean center TSE-positive PC scores is closer than the Mahalanobis distance from the unknown sample's PC scores to the mean center TSE-negative PC scores, the
10 unknown sample is classified as TSE-positive. Likewise, if the Mahalanobis distance from the unknown sample's PC scores to the mean center TSE-negative PC scores is closer than the Mahalanobis distance from the unknown sample's PC scores to the mean center TSE-positive PC scores, the unknown sample is classified as TSE-negative.

15 If both Mahalanobis distances (to the mean center TSE-negative PC scores and to the mean center TSE-positive PC scores) calculated during cross-validation of the calibration samples, during a validation sample test or during an unknown sample test are greater than 3, the sample is considered a Mahalanobis outlier. Such Mahalanobis outliers are considered a <No Test> result.
20 Mahalanobis outliers may be caused by improper sample trimming techniques or contamination/corruption of the tissue sample and may not result in a proper diagnosis. Thus, any samples tested via the method of the present invention that are Mahalanobis outliers can be removed from the calibration data set, and if the sample is a validation sample, will result in a <No Test> result.

25 The method of the present invention also includes updating the calibration data set for the particular animal species (deer, elk, sheep or goat) with correctly diagnosed "unknown" sample spectra in order to continually update the calibration set. This permits the calibration model to best account for possible variation, such as strain differentiation, typically found in naturally occurring
30 CWD or scrapie infections. As such, the calibration set for a given species can be continually optimized using samples from the same species that have been identified as TSE-positive and TSE-negative (and, if necessary, verified using

another conventionally known TSE testing method). In addition, calibration data sets can be developed and/or optimized not only for a particular species, but also for a particular geographical area, region or state, or a specific chemical, physiological or physical characteristic of a TSE.

- 5 In addition, the methods of the present invention include use of the validated diagnostic test/predictive model at several locations or laboratories in order to provide remote testing capabilities permitting researchers, farmers, and/or breeders the ability to correctly and rapidly diagnose an animal with a TSE.

10 Sample Scoring.

Samples tested in accordance with the present invention are scored with respect to a TSE-negative or TSE-positive result. Sample scores are calculated from the Mahalanobis distances determined from the unknown sample PC scores to the mean center of the TSE-positive cluster grouping and the mean center
15 TSE-negative cluster groupings. The score is calculated by subtracting the (Mahalanobis) distance to positive from the (Mahalanobis) distance to negative. (Reference is made to Example 5B and Fig. 18).

Any TSE-negative sample, as determined by the calibration model, having a calculated score ranging between about -0.1000 to 0.0000 may be
20 classified as <suspect positive>. For example a calculated score of -0.0900 would be classified as a <suspect positive> sample. Preferably, <suspect positive> samples are further tested by another TSE testing method such as by Western Blot assay.

In general, sample scoring permits the diagnosis of the sample to be
25 quantified, Thus, depending on the particular animal genotype or TSE strain, calculation of the sample score may be adjusted to increase the sensitivity of the test, perhaps, at the expense of specificity of the test. For example, sample scoring calculations may be adjusted to be more sensitive to, and therefore increase the incidence of, a <suspect positive> result, ensuring the number of
30 false negative results of the test are substantially zero.

After testing is completed on a sample, or alternatively, a group of samples, diagnosis reports can be generated. Such reports can contain animal

information, the origin of the animal, animal owner, diagnosis, lot information, etc. in order to provide researchers or governments with information for tracking and monitoring the animal and/or animal byproducts.

Thus, with reference to the preceding, the present invention includes, in part, an infrared spectroscopic method for developing a reference or calibration model for use in differentially diagnosing naturally occurring chronic wasting disease and/or scrapie, comprising (1) obtaining a plurality of known TSE-positive and known TSE-negative, untreated tissue samples from a given species to form a calibration set; (2) analyzing each sample in the calibration set using an IR spectrometric method and obtaining calibration IR spectral data for each known tissue sample in the calibration set; (3) applying a multivariate chemometric technique to the calibration IR spectral data for each sample to statistically differentiate the TSE-positive and TSE-negative calibration IR spectral data contained in the calibration set. The method can also include updating the calibration set with IR spectra of similar tissue samples from the same animal species and/or variety/breed that have been correctly diagnosed using the method of the present invention and verified via another TSE diagnostic technique. The method can include using tissue samples from the cortex or paracortex of a lymph node from the species, obex tissue from the brain of the animal and/or utilizing a blood sample from the animal. Preferably, the sample is irradiated at wavenumbers from about 4500 cm^{-1} to about 350 cm^{-1} .

In part, the present invention can include a method for detecting a transmissible spongiform encephalopathy in an animal selected from the group consisting of deer, elk, sheep and goat comprising selecting a sample from a live or postmortem subject to determine whether the subject has a transmissible spongiform encephalopathy; obtaining IR spectral data from the sample; and determining whether the sample is TSE-positive or TSE-negative by differentially comparing the IR spectral data of the sample with a calibration model comprising calibration IR spectral data from a plurality of known TSE-positive and known TSE-negative samples of similar type from the same species as the subject.

Accordingly, in part the present invention also includes a method for

detecting a TSE specific to a cervid, sheep or goat. The method comprises (1) obtaining a sample from one of a cervid, sheep or goat, (2) directing a beam of IR light at wavenumbers from about 4500 cm^{-1} to about 350 cm^{-1} to produce IR spectral data for the sample, (3) comparing the IR spectral data for the sample
5 with a calibration set of IR spectral data obtained through multivariate analysis of known TSE-positive and known TSE-negative samples, and (4) determining whether the sample is TSE-positive or TSE-negative from the calibration data set.

In part, the present invention is a method of detecting a change in spectral response between diseased and normal samples to differentially diagnose and/or
10 detect Chronic Wasting Disease. The method comprises (1) obtaining a sample from at least one of a lymph node containing cortex or paracortex tissue, obex tissue or blood from a cervid (2) directing a beam of IR light at wavenumbers from about 4500 cm^{-1} to about 350 cm^{-1} to produce IR spectral data for the sample, (3) comparing the IR spectral data for the sample with a calibration set of
15 infrared spectral data comprising both a CWD-positive and CWD-negative predictive model, and (4) determining whether variation in infrared absorption occurs in the sample, within at least one range of wavenumbers, due to the variation being characteristic of a positive indicator of CWD or a negative indicator of CWD.

The present invention also includes detecting a change in spectral response between diseased and normal samples to differentially diagnose and/or
20 detect scrapie. The method comprises (1) obtaining a sample from at least one of a lymph node containing cortex or paracortex tissue, obex tissue or blood from a sheep or a goat species, (2) directing a beam of IR light at wavenumbers from about 4500 cm^{-1} to about 350 cm^{-1} to produce IR spectral data for the sample, (3)
25 comparing the IR spectral data for the sample with a calibration set of infrared spectral data comprising both a scrapie-positive and scrapie-negative predictive model, and (4) determining whether variation in infrared absorption occurs in the sample, within at least one range of wavenumbers, due to the variation being
30 characteristic of a positive indicator of scrapie or a negative indicator of scrapie.

In part, the present invention is a method for rapidly screening samples for Chronic Wasting Disease or scrapie. The method comprises (1) analyzing an

untreated cortex or paracortex sample from the lymph node, untreated obex tissue or untreated blood from a cervid (if screening for CWD) or a sheep or goat species (if screening for scrapie) using an IR spectroscopic method providing IR spectral data, (2) applying principal component analysis to the IR spectral data
5 obtained from the sample and calculating the PCA scores for the unknown sample, and (3) differentially determining whether the sample is positive or negative for the TSE by comparing the PC scores for the sample with a calibration IR spectral data set comprising mean centered PC scores for the TSE-positive and TSE-negative samples in the calibration IR spectral data set. The
10 method can further include confirming of a positive CWD (or scrapie) diagnosis using a validated assay method such as immunohistochemistry.

Differentially determining whether the unknown sample is TSE-positive or TSE-negative can include calculation of the Mahalanobis distance from the unknown sample's PC scores to the mean centered PC scores for the TSE-
15 positive and TSE-negative sample groupings in the calibration spectral data set and determining whether the Mahalanobis distance from the unknown sample's PC scores is closer to the mean center TSE-positive PC scores or closer to the mean center TSE-negative PC scores.

Accordingly, it can be that in part, the present invention is a method for
20 monitoring chronic wasting disease and/or scrapie occurring within a particular region, state or country. The method comprises (1) presenting a hunter harvested, naturally postmortem or live animal species, (2) recording the originating location of the animal, (3) obtaining an untreated sample from the animal, the tissue sample selected from cortex or paracortex sample from the lymph node of
25 the animal, brain tissue or blood, (4) labeling the sample with computer readable indicia (such as a bar code) which includes but is not limited to the location of the animal, hunter/farmer information, and/or the date, (5) obtaining absorbance or emission spectral data for the sample at wavenumbers from about 7400 cm^{-1} to about 350 cm^{-1} , (6) comparing the spectral data to a reference set of spectral data,
30 (7) differentially identifying the sample as either positive or negative as indicated by the reference set of spectral data.

Moreover, the present invention includes, in part, a method of using

principal component analysis to discriminate between IR spectra of TSE-positive and TSE-negative samples. The method consists essentially of obtaining calibration IR absorbance spectra for a plurality of untreated known TSE-positive and untreated known TSE negative samples, applying principal component
5 analysis to the calibration IR absorbance spectra obtained for each of the known TSE-positive and known TSE-negative samples to statistically discriminate between the calibration IR absorbance spectra of the known TSE-positive samples and the known TSE-negative samples, calculating the TSE-positive mean center principal component scores for the known TSE-positive samples and
10 calculating the TSE-negative mean center principal component scores for the known TSE-negative samples, obtaining IR absorbance spectral data from an untreated, unknown sample, performing principal component analysis on the unknown sample including determining the principal component scores of the unknown sample and calculating a Mahalanobis distance from the principal component scores of the unknown sample to the TSE-positive mean center
15 principal component scores and calculating a Mahalanobis distance from the principal component scores of the unknown sample to the TSE-negative mean center principal component scores; whereby the unknown sample is classified as TSE-positive or TSE-negative.

20

Examples of the Invention.

The following non-limiting examples and data illustrate various aspects and features of the present invention, including the surprising and unexpected results obtained thereby. It should, of course, be understood that these examples
25 are included for illustrative purpose only and that the invention is not limited to the collection conditions, IR test instrumentation or the like set forth herein. Comparable utility and advantages can be realized using various other data analysis methodologies and/or embodiments consistent with the scope of this invention.

30

Test Equipment

All samples in the Examples that follow were scanned using a lab grade FTIR spectrometer (Nexus 670 by Thermo Nicolet, Inc., Madison, WI) including a standard mid-infrared source (7400-350 cm^{-1} , res. 0.125 cm^{-1}) and a DLaTGS
5 detector (deuterated triglycine sulphate doped with L-alanine) with KBr window and was equipped with a DuraSamplIR IITM 3-Reflection Diamond/ZnSe (SensIRTM Technologies, Danbury, CT). However, any commercially available infrared spectrophotometer may be utilized. Data collection and manipulation software OMNIC (© 2002 Thermo Electron Corporation) including TQ Analyst
10 software (© 2002 Thermo Electron Corporation), capable of performing principal component analysis, was included with the instrument and used to perform the statistical analysis. However, any computer program known to those skilled in the art may be used to carry out the statistical methods taught by the present invention.

15

Example 1 -- Development of a Calibration Model for Diagnosing CWD in Lymph Tissue

Tissue Handling

A retropharyngeal lymph node from each subject was sectioned to expose
20 the cortex and paracortex of the node, as illustrated in Fig. 1A.

An approximately about 1 cm x about 1 cm x about 0.2 cm section of a lymph node from a subject was then collected from the cortex or paracortex of the lymph node to obtain sample sections containing primary and/or secondary
25 follicles. Samples were trimmed, if required, to minimize medullary tissue within the sample. The exposed tissue was placed directly on the optical bench of the FTIR instrument without further work-up.

Sample Sources

With respect to the calibration model data, 29 known CWD positive and
30 34 known CWD negative samples were collected from white tailed deer in Nebraska and in Mississippi and were obtained from the U.S. Department of Agriculture/Agricultural Research Service in Pullman, Washington. An

additional 38 known positive samples and 26 known negative samples, taken from white tailed deer harvested during the 2002 deer hunting season, were obtained from the State of Wisconsin Department of Natural Resources. In all samples, a CWD diagnosis was predetermined using standard gold standard
5 methods such as by Western Blot assay or IHC.

The calibration data set, consisting of all 127 known samples, was used for spectral comparison via principal component analysis.

With respect to the validation data, 26 known positive samples and 59 known negative samples, taken from white tailed deer harvested during the 2002
10 deer hunting season, were obtained from the State of Wisconsin Department of Natural Resources. In all 85 samples, a CWD diagnosis was predetermined using IHC. The validation samples were obtained from different subjects than the samples used for the calibration set.

15 **Testing**

Each sample in the calibration and validation sets was scanned 64 times and co-added to increase the signal to noise ratio, thereby enhancing the spectral absorbance features of the sample. Complete scanning of each sample (including the 64 scans of the same sample) was performed in less than about one minute.
20 The FTIR data collection software, OMNIC/TQ Analyst (© 2002 Thermo Electron Corporation), collected the dispersive spectra for each sample. Figures 2 and 3 are representative of the raw spectral data obtained for a CWD-positive sample (Fig. 2) and a CWD-negative sample (Fig. 3).

After scanning, each tissue sample was returned to its sample container
25 for subsequent analysis by other methods.

FTIR Calibration for Chronic Wasting Disease

Calibration of the test for CWD was performed using discriminate principal component analysis performed with the analysis software described
30 herein. It will be appreciated by those skilled in the art that other multivariate chemometric techniques may be used for data analysis in developing the calibration/reference data set, including but not limited to, Partial Least Squares

Regression (PLS), Principal Component Regression (PCR), Multilinear Regression Analysis (MLR) and Discriminant Analysis.

The software was calibrated with the known CWD-positive and known CWD-negative samples to develop a calibration model specific for CWD (and/or PrP^{res}) in lymphoid tissue taken from cervids. Principal component analysis was performed on the calibration spectral data over the range from about 4500 cm⁻¹ to about 350 cm⁻¹ for each tissue sample in the calibration data set. As illustrated in Table 1, ten (10) principal components, accounting for about 98% of the variance in the calibration spectral data set were used for the calibration model.

10

TABLE 1
PRINCIPAL COMPONENT ANALYSIS OF
CALIBRATION DATA SET

<u>PRINCIPAL COMPONENT</u>	<u>% VARIANCE</u>	<u>CUMULATIVE VARIANCE</u>
1	58.989	58.989
2	19.922	78.912
3	9.077	87.988
4	4.490	92.479
5	2.481	94.960
6	1.172	96.132
7	0.760	96.891
8	0.451	97.342
9	0.355	97.697
10	0.273	97.970

15

A set of PC scores for each tissue sample in the calibration spectral data set was calculated. In addition, the mean center PC scores were generated for the known CWD-positive samples and the known CWD-negative samples.

20

The calibration set was cross-validated by calculating the Mahalanobis distances from each known sample in the calibration set to the mean center

CWD-positive PC scores and the mean center CWD-negative PC scores of the remaining known samples in the calibration set (e.g. by rotating each cross-validated sample out of the calibration set and calculating the Mahalanobis distances for that sample from the mean center CWD-positive PC scores and the mean center CWD-negative PC scores of the remaining known samples in the calibration set.)

As illustrated in Fig. 4, a scatter plot of the Mahalanobis distances for each calibration sample spectra depicts two distinct clusters of calibration data points, a first cluster grouping 20 corresponding to CWD-positive tissue samples and a second cluster grouping 22 corresponding to CWD-negative tissue samples. Figs. 5A and 5B contains a tabular representation of the data illustrating the actual class and the calculated class of the calibration data set. As illustrated in Figs. 5A and 5B, all calibration samples were correctly cross-validated as either CWD-positive or CWD-negative.

Consistent with the broader aspects of the invention, correlation between the present testing methodology and a validated TSE test will be evaluated by the kappa calculation; and agreement of less than 96% will result in recalibration of the system using additional refinement of the calibration spectrum examined, in particular, the calibration will be adjusted so that the sensitivity of the test approaches 100%. A slight decrease in test specificity (resulting in a small increase in false positive samples) is preferred in a pre-clinical screening test for TSEs. All TSE-positive diagnosis can be confirmed by IHC or other validated diagnostic test.

Validation of the Calibration Set for the Method for Detecting CWD in Lymph Tissue

Analysis of Validation Spectral Data Using the Predictive Model

Principal component analysis was performed on the spectral data for each validation tissue sample using the ten principal components identified in the calibration model. These spectral features were analyzed by PCA and the PC scores for each validation sample were determined.

The Mahalanobis distance for each validation sample in the validation set was determined from the PC scores of the specific validation sample and the mean center PC scores of the CWD positive cluster grouping of the calibration data set. Likewise, the Mahalanobis distance for each validation sample in the validation set was determined from the PC scores of the validation sample and the mean center PC scores of the CWD negative cluster grouping of the calibration data set. If the Mahalanobis distance from the validation sample's PC scores to the mean center CWD positive PC scores was closer than the Mahalanobis distance from the validation sample's PC scores to the mean center CWD negative PC scores, the validation sample was classified as CWD positive. Likewise, if the Mahalanobis distance from the validation sample's PC scores to the mean center CWD negative PC scores was closer than the Mahalanobis distance from the validation sample's PC scores to the mean center CWD positive PC scores, the validation sample was classified as TSE negative. Fig. 6 illustrates a scatter plot of the Mahalanobis distances for each validation sample. As can be seen, the validation samples are aligned with the two distinct clusters of groups of the calibration data set, and thus, each sample corresponds to either a CWD-positive disease state (triangular points 110) or a CWD-negative disease state (square points 112). As illustrated in Figs. 7A and 7B, each validation sample in the set of 85 samples were correctly diagnosed, thus, use of the present methodology revealed 100% agreement of the validation test results with the IHC results for each sample in the validation set.

Example 2 - Optimization of the Calibration and Validation Sets for Diagnosing Chronic Wasting Disease of Example 1

Calibration of Method for Chronic Wasting Disease

The calibration data set of Example 1 was optimized by removing sample number 95 from the sample set. As illustrated in Figs. 5A and 5B, this sample number resulted in a Mahalanobis distance of greater than 3. As such, the sample was considered a Mahalanobis outlier. According to the present methodology, such Mahalanobis outliers are considered a <No Test> result.

While sample number 95 was correctly cross-validated and diagnosed, as indicated in Example 1, it was removed from the calibration set for Example 2 in order to properly update the calibration model. Once removed from the calibration set, the principal components for the updated calibration model were recalculated as indicated below, and the Mahalanobis distances for each remaining sample were recalculated.

Ten principal components were used accounting for about 98% of the variability. These principal components are presented in Table 2.

10

TABLE 2
PRINCIPAL COMPONENT ANALYSIS OF OPTIMIZED
CALIBRATION DATA SET

<u>PRINCIPAL COMPONENT</u>	<u>% VARIANCE</u>	<u>CUMULATIVE VARIANCE</u>
1	62.251	62.251
2	18.181	80.433
3	6.692	87.124
4	5.048	92.172
5	2.427	94.599
6	1.862	96.461
7	0.505	96.966
8	0.427	97.393
9	0.270	97.663
10	0.272	97.936

A set of PC scores for each tissue sample in the calibration spectral data set was calculated. In addition, the mean center PC scores were generated for the known CWD-positive samples and the known CWD-negative samples.

The calibration set was cross-validated by calculating the Mahalanobis distances from each known sample in the calibration set to the mean center CWD-positive PC scores and the mean center CWD-negative PC scores of the remaining known samples in the calibration set, as in Example 1.

As illustrated in Fig. 8, a scatter plot of the Mahalanobis distances for each calibration sample spectra depicts two distinct clusters of calibration data points, a first cluster grouping 116 corresponding to CWD-positive tissue samples (triangular data points) and a second cluster grouping corresponding to
5 CWD-negative tissue samples (square data points).

Validation of Method for Chronic Wasting Disease

As illustrated in Figs. 7A and 7B, sample number 44 resulted in a Mahalanobis distance of greater than 3. As such, the sample was considered a
10 Mahalanobis outlier. According to the present methodology, such Mahalanobis outliers are considered a <No Test> result.

While sample number 44 was correctly cross-validated and diagnosed, as indicated in Example 1, it was removed from the validation set. The Mahalanobis distance for each validation sample in the validation set was
15 determined from the PC scores of validation sample and the mean center PC scores of the CWD positive cluster grouping of the optimized calibration data set. Likewise, the Mahalanobis distance for each validation sample in the validation set was determined from the PC scores of validation sample and the mean center PC scores of the CWD negative cluster grouping of the optimized calibration data
20 set. If the Mahalanobis distance from the validation sample PC scores to the mean center CWD positive PC scores was closer than the Mahalanobis distance from the validation sample PC scores to the mean center CWD-negative PC scores, the validation sample was classified as CWD positive. Likewise, if the Mahalanobis distance from the validation sample PC scores to the mean center
25 CWD negative PC scores was closer than the Mahalanobis distance from the validation sample PC scores to the mean center CWD positive PC scores, the validation sample was classified as TSE-negative. Fig. 9 illustrates a scatter plot of the Mahalanobis distances for each validation sample. As can be seen, the validation samples are aligned with the two distinct clusters of groups,
30 corresponding to either a CWD-positive disease state (triangular data points 120) or a CWD-negative disease state (square data points 122).

As illustrated in Fig. 9, each validation sample in the set of 84 samples were correctly diagnosed, thus, use of the present methodology revealed 100% agreement of the validation test results with the IHC results for each sample in the validation set.

5

Example 3 -- Development of a Calibration Model for Diagnosing Scrapie in Lymph Tissue

Tissue Handling

10 A retropharyngeal lymph node from each subject was sectioned to expose the cortex and paracortex of the node, as illustrated in Fig. 1A.

An approximately about 1 cm x about 1 cm x about 0.2 cm section of a lymph node from a subject was then collected from the cortex or paracortex of the lymph node to obtain sample sections containing primary and/or secondary follicles. Samples were trimmed, if required, to minimize medullary tissue within the sample. The exposed tissue was placed directly on the optical bench of the FTIR instrument without further work-up.

15

Sample Sources

20 With respect to the calibration model data, 10 known samples positive for naturally occurring scrapie and 20 known negative samples were collected from sheep in the state(s) of Ohio, Montana, South Dakota, and Washington were provided by the U.S. Department of Agriculture/Agricultural Research Service in Pullman, Washington. In all samples, a scrapie diagnosis was predetermined using standard gold standard methods such as by Western Blot assay or IHC.

25

The calibration data set was then used for spectral comparison via principal component analysis that consisted of all 30 known samples.

30 With respect to the validation data, 5 known samples positive for naturally occurring scrapie and 10 known negative samples were obtained. The lymph nodes were sectioned as described previously herein. In all 15 samples, a scrapie diagnosis was predetermined using IHC. The validation samples were obtained from different subjects than the samples used for the calibration set.

Testing

Each sample in both the calibration set and the validation set were scanned 64 times and co-added to increase the signal to noise ratio, thereby enhancing the spectral absorbance features of the sample. Complete scanning of each sample (including the 64 scans of the same sample) was performed in less than about one minute. The FTIR data collection software, OMNIC/TQ Analyst (© 2002 Thermo Electron Corporation), collected the dispersive spectra for each sample.

10 **FTIR Calibration for Scrapie in Sheep**

Calibration of the test for scrapie was performed using discriminate principal component analysis performed with the analysis software described herein. As in Examples 1 and 2, it will be appreciated by those skilled in the art that other multivariate chemometric techniques may be used for data analysis in developing the calibration/reference data set, including but not limited to, Partial Least Squares Regression (PLS), Principal Component Regression (PCR), Multilinear Regression Analysis (MLR) and Discriminant Analysis.

The software was calibrated with the known scrapie-positive and scrapie-negative samples to develop a calibration model specific for scrapie infections in lymphoid tissue taken from sheep. Principal component analysis was performed on the calibration spectral data over the range from about 4500 cm^{-1} to about 350 cm^{-1} for each tissue sample in the calibration data set. As illustrated in Table 3, ten (10) principal components, accounting for over 98% of the variance in the calibration spectral data set were used for the calibration model.

25

TABLE 3**PRINCIPAL COMPONENT ANALYSIS OF CALIBRATION DATA SET**

<u>PRINCIPAL COMPONENT</u>	<u>% VARIANCE</u>	<u>CUMULATIVE VARIANCE</u>
1	68.255	68.255
2	21.139	89.394

3	4.038	93.433
4	1.713	95.146
5	0.989	96.135
6	0.618	96.753
7	0.520	97.272
8	0.348	97.621
9	0.353	97.974
10	0.291	98.264

A set of PC scores for each tissue sample in the calibration spectral data set was calculated. In addition, the mean center PC scores were generated for the samples known to be positive for scrapie and the samples known to be negative.

The calibration set was cross-validated by calculating the Mahalanobis distances from each known sample in the calibration set to the mean center scrapie-positive PC scores and the mean center scrapie-negative PC scores of the remaining known samples in the calibration set (e.g. by rotating each cross-validated sample out of the calibration set and calculating the Mahalanobis distances for that sample from the mean center scrapie-positive PC scores and the mean center scrapie-negative PC scores of the remaining known samples in the calibration set.)

As illustrated in Fig. 10, a scatter plot of the Mahalanobis distances for each calibration sample spectra depicts two distinct clusters of calibration data points, a first cluster grouping corresponding 130 to scrapie-positive tissue samples (triangular data points) and a second cluster grouping corresponding 132 to scrapie-negative tissue samples (square data points). Fig. 11 contains a tabular representation of the calibration data samples illustrating the actual class and the calculated class for each sample of the calibration data set. As illustrated in Fig. 11, all calibration samples were correctly cross-validated as either scrapie-positive or scrapie-negative.

Validation of the Calibration Set for the Method for Detecting Scrapie in

Lymph Tissue

Analysis of Validation Spectral Data Using the Predictive Model

Principal component analysis was then performed on the spectral data for each validation tissue sample using the ten principal components identified in the calibration model. These spectral features were analyzed by PCA and the PC scores for each validation sample were determined, as described with reference to Example 1..

The Mahalanobis distance for each validation sample in the validation set was determined from the PC scores of validation sample and the mean center PC scores of the scrapie-positive cluster grouping of the calibration data set. Likewise, the Mahalanobis distance for each validation sample in the validation set was determined from the PC scores of validation sample and the mean center PC scores of the scrapie-negative cluster grouping of the calibration data set. If the Mahalanobis distance from the validation sample's PC scores to the mean center scrapie-positive PC scores was closer than the Mahalanobis distance from the validation sample's PC scores to the mean center scrapie-negative PC scores, the validation sample was classified as positive for scrapie. Likewise, if the Mahalanobis distance from the validation sample's PC scores to the mean center scrapie-negative PC scores was closer than the Mahalanobis distance from the validation sample's PC scores to the mean center scrapie-positive PC scores, the validation sample was classified as scrapie-negative. Fig. 12 illustrates a scatter plot of the Mahalanobis distances for each validation sample, along with the calibration data points. As can be seen, the validation samples fall into the two distinct clusters of groups, corresponding to a scrapie-positive disease state (triangular data points 136) and scrapie-negative disease state (square data points 138).

As illustrated in Fig. 13, each validation sample in the set of 15 samples were correctly diagnosed, thus, use of the present methodology revealed 100% agreement of the validation test results with the IHC results for each sample in the validation set.

Example 4 - Development of a Calibration Model for Diagnosing Scrapie in Whole Blood

Sample Sources

With respect to the calibration model data, 3 known whole blood samples
5 positive for naturally occurring scrapie and 7 known negative whole blood
samples were provided by the U.S. Department of Agriculture/Agricultural
Research Service in Pullman, Washington. With respect to the validation data, 1
known positive, whole blood sample and 1 known negative, whole blood sample
(sample numbers 11 and 12 on Fig. 15) were obtained. In all samples, a scrapie
10 diagnosis was predetermined using standard gold standard methods such as by
Western Blot assay or IHC.

It will be appreciated by those skilled in the art that although previously
frozen samples are used in the present example, freshly drawn blood samples
from live animals or freshly drawn samples from animals prior to
15 slaughtering/sacrificing can be used in the present invention.

Testing

Approximately about 10 μ l of untreated, whole blood from each sample
subject was utilized. Blood samples were pipetted directly onto the optical
20 platform of the instrument. Each sample in both the calibration set and the
validation set were scanned 64 times and co-added to increase the signal to noise
ratio, thereby enhancing the spectral absorbance features of the sample.
Complete scanning of each sample (including the 64 scans of the same sample)
was performed in less than about one minute. The FTIR data collection software,
25 OMNIC/TQ Analyst (\textcopyright 2002 Thermo Electron Corporation), collected the
dispersive spectra for each sample.

FTIR Calibration for Scrapie in Sheep

Second derivatives were calculated from the original spectra for each
30 sample in the calibration data set using a Savitzky-Golay smoothing algorithm
using the aforementioned software. Calibration of the test for scrapie was then
performed using discriminate principal component analysis performed with the

analysis software described herein. As in Examples 1 through 3, it will be appreciated by those skilled in the art that other multivariate chemometric techniques may be used for data analysis in developing the calibration/reference data set.

5 The software was calibrated with the known scrapie-positive and scrapie-negative samples to develop a calibration model specific for scrapie infections in whole blood taken from sheep. Principal component analysis was performed on the calibration spectral data over the range from about 4500 cm^{-1} to about 350 cm^{-1} for each blood sample in the calibration data set. As illustrated in Table 4,
10 nine (9) principal components, accounting for about 99% of the variance in the calibration spectral data set were used for the calibration model.

TABLE 4
PRINCIPAL COMPONENT ANALYSIS OF CALIBRATION DATA SET

15

<u>PRINCIPAL COMPONENT</u>	<u>% VARIANCE</u>	<u>CUMULATIVE VARIANCE</u>
1	63.605	63.605
2	17.623	81.228
3	6.354	87.582
4	3.825	91.408
5	2.653	94.061
6	1.667	95.728
7	1.512	97.240
8	0.979	98.220
9	0.769	98.989

A set of PC scores for each tissue sample in the calibration spectral data set was calculated. In addition, the mean center PC scores were generated for the samples known to be positive for scrapie and the samples known to be negative.

20 The calibration set was cross-validated by calculating the Mahalanobis distances from each known sample in the calibration set to the mean center scrapie-positive PC scores and the mean center scrapie-negative PC scores of the

remaining known samples in the calibration set (e.g. by rotating each cross-validated sample out of the calibration set and calculating the Mahalanobis distances for that sample from the mean center scrapie-positive PC scores and the mean center scrapie-negative PC scores of the remaining known samples in the calibration set.)

As illustrated in Fig. 14, a scatter plot of the Mahalanobis distances for each calibration sample spectra depicts two distinct clusters of calibration data points (unshaded points), a first cluster grouping 140 corresponding to scrapie-positive tissue samples (triangular unshaded points) and a second cluster grouping corresponding 142 to scrapie-negative tissue samples (square unshaded points). Fig. 15 contains a tabular representation of the calibration data samples (sample numbers 1 through 10) illustrating the actual class and the calculated class for each sample of the calibration data set. All calibration samples were correctly cross-validated as either scrapie-positive or scrapie-negative.

15

Validation of the Calibration Set for the Method for Detecting Scrapie in Whole Blood

Analysis of Validation Spectral Data Using the Predictive Model

Second derivatives were calculated from the original spectra for each sample in the validation data set using a Savitzky-Golay smoothing algorithm using the aforementioned software. Principal component analysis was then performed on the spectral data for each validation sample using the ten principal components identified in the calibration model. These spectral features were analyzed by PCA and the PC scores for each validation sample were determined.

The Mahalanobis distance for each validation sample in the validation set was determined from the PC scores of validation sample and the mean center PC scores of the scrapie-positive cluster grouping of the calibration data set. Likewise, the Mahalanobis distance for each validation sample in the validation set was determined from the PC scores of validation sample and the mean center PC scores of the scrapie-negative cluster grouping of the calibration data set. If the Mahalanobis distance from the validation sample's PC scores to the mean center scrapie-positive PC scores was closer than the Mahalanobis distance from

the validation sample's PC scores to the mean center scrapie-negative PC scores, the validation sample was classified as positive for scrapie. Likewise, if the Mahalanobis distance from the validation sample's PC scores to the mean center scrapie-negative PC scores was closer than the Mahalanobis distance from the validation sample's PC scores to the mean center scrapie-positive PC scores, the validation sample was classified as scrapie-negative. Fig. 14 illustrates a scatter plot of the Mahalanobis distances for each validation sample (shaded points), along with the calibration data points (unshaded points). As can be seen, each validation sample falls into one of the two distinct clusters of groups, corresponding to either a scrapie-positive (sample number 12, triangular shaded point 144) or scrapie-negative (sample number 11, square shaded point 146) disease state.

As illustrated in Fig. 15, each validation sample was correctly diagnosed, thus, use of the present methodology revealed 100% agreement of the validation test results with the IHC results for each sample in the validation set.

Example 5A - Development of a Calibration Model for Diagnosing Scrapie in Blood Serum

Sample Sources

With respect to the calibration model data, 23 known blood serum samples positive for naturally occurring scrapie and 10 known negative blood serum samples were obtained from the U.S. Department of Agriculture/Agricultural Research Service in Pullman, Washington. With respect to the validation data, 1 known positive, blood serum sample and 1 known negative, blood serum sample (sample numbers 9 and 35 on Fig. 17) were also obtained.

In all samples, a scrapie diagnosis was predetermined using standard gold standard methods such as by Western Blot assay or IHC.

Testing

Approximately about 10 μ l of untreated, blood serum from each sample subject was utilized. Blood samples were pipetted directly onto the optical platform of the instrument. Each sample in both the calibration set and the

validation set were scanned as described with reference to Example 4.

FTIR Calibration for Scrapie in Sheep

5 Second derivatives were calculated from the original spectra for each sample in the calibration data set using a Savitzky-Golay smoothing algorithm using the aforementioned software. Calibration of the test for scrapie was then performed using discriminate principal component analysis performed with the analysis software described herein.

10 The software was calibrated with the known scrapie-positive and scrapie-negative samples to develop a calibration model specific for scrapie infections in blood serum taken from sheep. Principal component analysis was performed on the calibration spectral data over the range from about 4500 cm^{-1} to about 350 cm^{-1} for each serum sample in the calibration data set. As illustrated in Table 5, fifteen (15) principal components, accounting for over 99% of the variance in the
15 calibration spectral data set were used for the calibration model.

TABLE 5
PRINCIPAL COMPONENT ANALYSIS OF CALIBRATION DATA SET

20

<u>PRINCIPAL COMPONENT</u>	<u>% VARIANCE</u>	<u>CUMULATIVE VARIANCE</u>
1	90.192	90.192
2	4.207	94.400
3	2.420	96.819
4	0.663	97.482
5	0.439	97.921
6	0.324	98.245
7	0.254	98.499
8	0.184	98.683
9	0.180	98.863
10	0.152	99.016

11	0.126	99.142
12	0.103	99.245
13	0.092	99.337
14	0.088	99.426
15	0.073	99.499

A set of PC scores for each tissue sample in the calibration spectral data set was calculated. In addition, the mean center PC scores were generated for the samples known to be positive for scrapie and the samples known to be negative.

5 The calibration set was cross-validated as described with reference to Example 4. As illustrated in Fig. 16, a scatter plot of the Mahalanobis distances for each calibration sample spectra depicts two distinct clusters of calibration data points (unshaded points), a first cluster grouping 150 corresponding to scrapie-positive tissue samples (triangular unshaded points) and a second cluster
10 grouping 152 corresponding to scrapie-negative tissue samples (square unshaded points). Fig. 17 contains a tabular representation of the calibration data samples (sample numbers 1 through 8 and 10 through 34) illustrating the actual class and the calculated class for each sample of the calibration data set. All calibration samples were correctly cross-validated as either scrapie-positive or scrapie-
15 negative.

Validation of the Calibration Set for the Method for Detecting Scrapie in Blood Serum

Analysis of Validation Spectral Data Using the Predictive Model

20 Second derivatives were calculated from the original spectra for each sample in the validation data set using a Savitzky-Golay smoothing algorithm using the aforementioned software. Principal component analysis was then performed on the spectral data for each validation sample using the ten principal components identified in the calibration model. These spectral features were
25 analyzed by PCA and the PC scores for each validation sample were determined.

The Mahalanobis distance for each validation sample in the validation set was determined as described with reference to Example 4. Fig. 16 illustrates a

scatter plot of the Mahalanobis distances for each validation sample (shaded points), along with the calibration data points (unshaded points). As can be seen, each validation sample falls into one of the two distinct clusters of groups, corresponding to either a scrapie-positive (sample number 35, triangular shaded point 154) or scrapie-negative (sample number 9, square shaded point 156) disease state.

As illustrated in Fig. 17, each validation sample was correctly diagnosed, thus, use of the present methodology revealed 100% agreement of the validation test results with the IHC results for each sample in the validation set.

10

Example 5B - Sample Scoring

Each calibration and validation sample in Example 5A was scored for the presence of scrapie in the sample. As illustrated in Fig. 18, a score was calculated for each sample by subtracting the distance to positive from the distance to negative. If a sample score falls within the range of -0.1000 to 0.0000, the sample is classified as <suspect positive>. As shown in Fig. 18, none of the samples tested were classified as <suspect positive> samples.

Example 6 - Development of a Calibration Model for Diagnosing Scrapie in Blood Plasma

Sample Sources

With respect to the calibration model data, 27 known blood plasma samples positive for naturally occurring scrapie and 34 known negative blood plasma samples were obtained from the U.S. Department of Agriculture/Agricultural Research Service in Pullman, Washington. With respect to the validation data, 1 known positive, blood plasma sample and 1 known negative, blood plasma sample (sample numbers 33 and 53 on Fig. 19) were also provided.

In all samples, a scrapie diagnosis was predetermined using standard gold standard methods such as by Western Blot assay or IHC.

30

Testing

Approximately about 10 μ l of untreated, blood plasma from each sample

subject was utilized. Blood plasma samples were pipetted directly onto the optical platform of the instrument. Each sample in both the calibration set and the validation set were scanned as described with reference to Example 4.

5 **FTIR Calibration for Scrapie in Sheep**

Second derivatives were calculated from the original spectra for each sample in the calibration data set using a Savitzky-Golay smoothing algorithm using the aforementioned software. Calibration of the test for scrapie was then performed using discriminate principal component analysis performed with the analysis software described herein.

The software was calibrated with the known scrapie-positive and scrapie-negative samples to develop a calibration model specific for scrapie infections in blood plasma taken from sheep. Principal component analysis was performed on the calibration spectral data over the range from about 4500 cm^{-1} to about 350 cm^{-1} for each plasma sample in the calibration data set. As illustrated in Table 6, twenty-four (24) principal components, accounting for over 96% of the variance in the calibration spectral data set were used for the calibration model.

20 **TABLE 6**
PRINCIPAL COMPONENT ANALYSIS OF CALIBRATION DATA SET

<u>PRINCIPAL COMPONENT</u>	<u>% VARIANCE</u>	<u>CUMULATIVE VARIANCE</u>
1	31.476	31.476
2	20.793	52.270
3	14.990	67.260
4	5.604	72.864
5	3.489	76.353
6	3.282	79.635
7	2.900	82.535
8	2.062	84.596
9	1.822	86.419

10	1.546	87.965
11	1.169	89.134
12	1.148	90.283
13	0.994	91.277
14	0.720	91.997
15	0.745	92.742
16	0.638	93.380
17	0.620	93.999
18	0.541	94.540
19	0.468	95.008
20	0.377	95.385
21	0.371	95.756
22	0.315	96.071
23	0.284	96.355
24	0.281	96.637

A set of PC scores for each tissue sample in the calibration spectral data set was calculated. In addition, the mean center PC scores were generated for the samples known to be positive for scrapie and the samples known to be negative.

- 5 The calibration set was cross-validated as described with reference to Example 4. As illustrated in Fig. 19, a scatter plot of the Mahalanobis distances for each calibration sample spectra depicts two distinct clusters of calibration data points (unshaded points), a first cluster grouping 160 corresponding to scrapie-positive tissue samples (triangular unshaded points) and a second cluster
- 10 grouping 162 corresponding to scrapie-negative tissue samples (square unshaded points). Fig. 20 contains a tabular representation of the calibration data samples (sample numbers 1 through 32, 34 through 52, and 54 through 63) illustrating the actual class and the calculated class for each sample of the calibration data set. All calibration samples were correctly cross-validated as either scrapie-positive
- 15 or scrapie-negative.

Validation of the Calibration Set for the Method for Detecting Scrapie in Blood Plasma

Analysis of Validation Spectral Data Using the Predictive Model

5 Second derivatives were calculated from the original spectra for each sample in the validation data set using a Savitzky-Golay smoothing algorithm using the aforementioned software. Principal component analysis was then performed on the spectral data for each validation sample using the ten principal components identified in the calibration model. These spectral features were analyzed by PCA and the PC scores for each validation sample were determined.

10 The Mahalanobis distance for each validation sample in the validation set was determined as described with reference to Example 4. Fig. 19 illustrates a scatter plot of the Mahalanobis distances for each validation sample (shaded points), along with the calibration data points (unshaded points). As can be seen, each validation sample falls into one of the two distinct clusters of groups, 15 corresponding to either a scrapie-positive (sample number 33, triangular unshaded point 164) or scrapie-negative (sample number 53, square shaded point 164) disease state.

As illustrated in Fig. 20, each validation sample was correctly diagnosed, thus, use of the present methodology revealed 100% agreement of the validation 20 test results with the IHC results for each sample in the validation set.

We Claim:

- 1 1. A method for developing a calibration model for use in differentially
2 diagnosing naturally occurring chronic wasting disease (CWD) in a cervid, said
3 method comprising:
 - 4 obtaining a plurality of known CWD-positive and known CWD-negative
5 tissue samples to form a calibration set;
 - 6 analyzing each of the known CWD-positive tissue samples and each of
7 the known CWD-negative tissue samples in the calibration set using an IR
8 spectrometric method;
 - 9 obtaining at least one set of calibration IR spectral data for each of the
10 known CWD-positive and known CWD-negative tissue samples in the calibration
11 set; and
 - 12 applying a multivariate chemometric technique to the calibration IR
13 spectral data for each of the known CWD-positive tissue samples and each of the
14 known CWD-negative tissue samples to statistically differentiate the CWD-
15 positive and CWD-negative calibration IR spectral data contained in the
16 calibration set.
- 1 2. The method of Claim 1, wherein the tissue sample substantially untreated.
- 1 3. The method of Claim 1, wherein each of the known CWD-positive and
2 the known CWD-negative tissue samples are lymph tissue samples including a
3 substantial portion of primary follicles, secondary follicles or a combination
4 thereof.
- 1 4. The method of Claim 1, wherein the spectrometric method is one of an
2 absorption and a reflectance spectrometric method.
- 1 5. The method of Claim 1, wherein each of the known CWD-positive and
2 known CWD-negative tissue samples in the calibration set is analyzed at
3 wavenumbers from about 4500 cm^{-1} to about 350 cm^{-1} .

1 6. The method of Claim 1, wherein principal component analysis is applied
2 to the calibration spectral data obtained for each of the known CWD-positive
3 tissue samples and each of the known CWD-negative tissue samples to
4 statistically differentiate the CWD-positive and CWD-negative calibration
5 spectral data contained in the calibration set.

1 7. The method of Claim 6, further comprising calculating CWD-positive
2 mean center principal component scores for the known CWD-positive tissue
3 samples and CWD-negative mean center principal component scores for the
4 known CWD-negative tissue samples.

1 8. The method of Claim 7, further comprising analyzing an unknown tissue
2 sample using a spectrometric method, obtaining at least one set of spectral data
3 for the unknown tissue sample, calculating the principal component scores of the
4 unknown tissue sample, comparing the principal component scores of the
5 unknown sample to the CWD-positive mean center principal component scores
6 and the CWD-negative mean center principal component scores; and classifying
7 the unknown tissue sample as one of CWD-positive and CWD-negative.

1 9. The method of Claim 8, further comprising calculating a Mahalanobis
2 distance from the principal component scores of the unknown sample to each of
3 the CWD-positive and CWD-negative mean centered principal component
4 scores, wherein the unknown tissue sample is classified as CWD-positive, CWD-
5 negative or a Mahalanobis outlier.

1 10. The method of Claim 1, further comprising normalizing each of said sets
2 of spectral data prior to applying said multivariate chemometric technique to the
3 calibration spectral data to reduce noise and adjust for drift and diffuse light
4 scatter.

1 11. The method of Claim 1, further comprising analyzing an unknown,
2 untreated tissue sample using a spectrometric method, obtaining at least one set

3 of spectral data for the unknown tissue sample, applying a multivariate
4 chemometric technique to the spectral data for the unknown tissue sample,
5 comparing the spectral data of the unknown sample to the calibration spectral
6 data of the known CWD-positive and the known CWD-negative tissue samples,
7 whereby said unknown sample is classified as one of CWD-positive and CWD-
8 negative.

1 12. The method of Claim 11, further comprising updating the calibration set
2 with the spectral data obtained for said unknown tissue sample.

1 13. A method for detecting a transmissible spongiform encephalopathy (TSE)
2 in a cervid, sheep or goat, said method comprising:
3 selecting a raw, unknown sample from a live or postmortem subject;
4 obtaining at least one set of IR spectral data from the sample; and
5 comparing the IR spectral data of the sample with a calibration model
6 comprising IR spectral data from a plurality of known TSE-positive and known
7 TSE-negative samples of similar type from the same species as the subject to
8 determine whether the sample is TSE-positive or TSE-negative.

1 14. The method of Claim 13, wherein the untreated, unknown sample is
2 selected from the group consisting of lymph tissue, brain tissue and blood.

1 15. The method of Claim 13, wherein infrared absorbance spectra for the
2 unknown sample and each of the known samples are obtained at wavenumbers
3 from about 7400 cm^{-1} to about 350 cm^{-1} .

1 16. The method of Claim 13, wherein the calibration model includes spectral
2 data from a plurality of known TSE-positive and known TSE-negative samples
3 subjected to a spectral data compression technique selected from the group
4 consisting of Principal Component Analysis (PCA), Partial Least Squares
5 Regression (PLS), Principal Component Regression (PCR), Multiple Linear
6 Regression (MLR) and Discriminant Analysis.

1 17. The method of Claim 16, wherein the spectral data of the unknown
2 sample is subjected to a spectral data compression technique and wherein the
3 compressed spectral data of the unknown sample is compared to the calibration
4 model, wherein the unknown sample is classified as TSE-positive or TSE-
5 negative.

1 18. A method of detecting a change in spectral response between diseased and
2 normal samples to differentially diagnose a transmissible spongiform
3 encephalopathy (TSE) in a cervid, sheep or goat, said method comprising:
4 obtaining a sample from at least one of a lymph node containing cortex
5 or paracortex tissue, brain tissue or blood from a subject;
6 directing a beam of IR light at wavenumbers from about 7400 cm^{-1} to
7 about 350 cm^{-1} to produce IR spectral data for the sample;
8 comparing the IR spectral data for the sample with a calibration set of IR
9 spectral data comprising both a TSE-positive and a TSE-negative predictive
10 model; and
11 determining whether variation in absorption occurs in the sample, the
12 variation being characteristic of one of a TSE-positive or a TSE-negative
13 condition.

1 19. The method of Claim 18, wherein the calibration set of spectral data is
2 obtained through multivariate analysis of known TSE-positive and known TSE-
3 negative samples from the same species as the subject.

1 20. The method of Claim 19, wherein the spectral data of the unknown
2 sample is subjected to multivariate analysis and compared to the calibration set of
3 spectral data, whereby the variation in absorption in the unknown sample
4 indicates one of a TSE-positive or a TSE-negative condition.

1 21. A method for rapidly screening unknown samples for a TSE in cervids,
2 sheep or goats, said method comprising:
3 analyzing an untreated sample selected from lymph tissue, brain tissue or

4 plasma using an IR spectroscopic method providing IR spectral data;
5 applying principal component analysis to the IR spectral data obtained
6 from the unknown sample and calculating the principal component scores for the
7 unknown sample; and
8 differentially determining whether the sample is TSE-positive or TSE-negative
9 by comparing the principal component scores for the unknown sample with a
10 calibration IR spectral data set comprising a set of mean centered principal
11 component scores for each of a known TSE-positive sample grouping and a
12 known TSE-negative sample grouping from the same species as the subject.

1 22. The method of Claim 21, wherein spectral data for the unknown sample
2 and each of the known samples are obtained at wavenumbers from about 7400
3 cm^{-1} to about 350 cm^{-1} .

1 23. The method of Claim 21, wherein differentially determining whether the
2 unknown sample is TSE-positive or TSE-negative includes calculation of a
3 Mahalanobis distance from the principal component scores of the unknown
4 sample to the mean centered principal component scores for each of the TSE-
5 positive and the TSE-negative sample groupings in the calibration spectral data
6 set and determining whether the Mahalanobis distance from the principal
7 component scores of the unknown sample is closer to the mean center TSE-
8 positive principal component scores or closer to the mean center TSE-negative
9 principal component scores.

1 24. The method of Claim 21, further comprising confirming of a TSE-positive
2 diagnosis using a secondary diagnosis method selected from the group consisting
3 of immunohistochemistry assay, Western Blot assay and microscopic
4 examination.

1 25. A method for monitoring Chronic Wasting Disease within a particular
2 region, state or country, the method comprising:
3 presenting a hunter harvested or naturally postmortem animal species;

4 recording the originating location of the postmortem animal;
5 obtaining a raw, untreated sample from one of a lymph node, brain tissue
6 or blood plasma of the animal;
7 labeling the sample with computer readable indicia including at least one
8 of the location of the animal, hunter information and the date;
9 obtaining IR spectral data for the sample at wavenumbers from about
10 7400 cm^{-1} to about 350 cm^{-1} ,
11 comparing the IR spectral data to a reference set of IR spectral data; and
12 differentially identifying the sample as either CWD-positive or CWD-negative as
13 indicated by the reference set of IR spectral data.

1 26. The method of Claim 25, wherein the spectral data of the sample is
2 obtained using Fourier transform infrared spectroscopy.

1 27. The method of Claim 25, wherein the reference set of spectral data is
2 developed by: analyzing a plurality of known CWD-positive samples and a
3 plurality of known CWD-negative samples using a spectrometric method at
4 wavenumbers from about 7400 cm^{-1} to about 350 cm^{-1} and generating predicted
5 scores for each of the CWD-positive and CWD-negative sample groupings using
6 a multivariate technique.

1 28. The method of Claim 27, wherein predicted scores for the unknown
2 sample are compared with the CWD-positive predicted scores and CWD-negative
3 predicted scores to identify the sample as either CWD-positive or CWD-negative.

1 29. The method of Claim 25, further comprising incorporating IR spectral
2 data from a correctly diagnosed sample into the reference set of spectral data.

FIG. 1A






FIG. 1B



3/23

FIG. 2



4/23

FIG. 3




FIG. 4




FIG. 5A

CALIBRATION RESULTS TABLE

Sample Number	Actual Class	Calculated Class	Distance to Negative	Distance to Positive	Sample Number	Actual Class	Calculated Class	Distance to Negative	Distance to Positive
1	Positive	Positive	2.4079	0.7795	39	Negative	Negative	0.6525	2.0371
2	Positive	Positive	2.1531	0.9518	40	Negative	Negative	0.7608	1.9144
3	Positive	Positive	1.7942	0.5148	41	Negative	Negative	0.7496	2.0833
4	Positive	Positive	2.0154	0.6727	42	Negative	Negative	0.7112	1.9942
5	Positive	Positive	2.3145	1.1799	43	Negative	Negative	0.6256	1.6253
6	Positive	Positive	1.8879	0.9960	44	Negative	Negative	0.5704	1.9880
7	Positive	Positive	2.3234	0.7767	45	Negative	Negative	0.4781	2.1435
8	Positive	Positive	2.0632	0.5733	46	Negative	Negative	0.4098	2.1139
9	Positive	Positive	1.7208	1.2076	47	Negative	Negative	0.8195	2.1369
10	Positive	Positive	2.1764	0.6018	48	Negative	Negative	0.9326	2.2511
11	Positive	Positive	2.5735	0.9321	49	Negative	Negative	1.0957	2.4425
12	Positive	Positive	2.3006	0.6908	50	Negative	Negative	0.9055	2.2251
13	Positive	Positive	2.0930	0.8521	51	Negative	Negative	1.0548	2.1914
14	Positive	Positive	2.2427	0.8151	52	Negative	Negative	0.9629	2.2088
15	Positive	Positive	2.4505	1.0848	53	Negative	Negative	0.8270	1.8917
16	Positive	Positive	2.4322	1.0959	54	Negative	Negative	0.9303	2.2535
17	Positive	Positive	2.1662	0.8309	55	Negative	Negative	0.8707	1.8776
18	Positive	Positive	2.2438	0.9259	56	Negative	Negative	0.8431	1.9679
19	Positive	Positive	2.2977	1.1509	57	Negative	Negative	0.8496	1.9161
20	Positive	Positive	2.2273	0.8207	58	Negative	Negative	1.1759	2.4057
21	Positive	Positive	2.8980	1.3577	59	Negative	Negative	1.2338	2.2505
22	Positive	Positive	2.5990	0.9703	60	Negative	Negative	1.0931	1.7391
23	Positive	Positive	1.2984	1.0586	61	Negative	Negative	0.8621	1.9236
24	Positive	Positive	1.2942	0.8831	62	Negative	Negative	0.9718	2.0011
25	Positive	Positive	1.6078	0.7088	63	Negative	Negative	1.0822	2.1547
26	Positive	Positive	1.6106	0.8799	64	Negative	Negative	0.5606	2.0898
27	Positive	Positive	1.4955	0.8553	65	Negative	Negative	0.8281	2.2234
28	Positive	Positive	1.4813	0.6518	66	Negative	Negative	0.7228	2.2651
29	Positive	Positive	1.8072	0.5948	67	Negative	Negative	1.0875	1.8829
30	Negative	Negative	0.6228	1.7093	68	Negative	Negative	0.8019	1.8813
31	Negative	Negative	0.6858	2.1300	69	Negative	Negative	0.8879	2.0348
32	Negative	Negative	0.8516	2.1816	70	Negative	Negative	1.0368	2.0748
33	Negative	Negative	0.9111	2.1806	71	Negative	Negative	1.1952	2.2006
34	Negative	Negative	0.8740	2.1989	72	Negative	Negative	0.5115	1.9598
35	Negative	Negative	0.8748	2.2441	73	Negative	Negative	0.6433	1.8511
36	Negative	Negative	0.8908	2.4774	74	Negative	Negative	0.6488	1.7105
37	Negative	Negative	0.7338	2.0939					
38	Negative	Negative	0.9803	2.3438					


FIG. 5B

CALIBRATION RESULTS TABLE

Sample Number	Actual Class	Calculated Class	Distance to		Sample Number	Actual Class	Calculated Class	Distance to	
			Negative	Positive				Negative	Positive
75	Negative	Negative	1.1330	1.9901	107	Positive	Positive	1.5388	0.9626
76	Negative	Negative	0.8292	1.6300	108	Positive	Positive	1.7363	0.8860
77	Negative	Negative	0.6297	2.0666	109	Positive	Positive	2.0651	1.1417
78	Negative	Negative	0.7638	1.7142	110	Positive	Positive	1.7891	1.2774
79	Negative	Negative	0.6496	2.1150	111	Positive	Positive	1.8844	0.8452
80	Negative	Negative	0.5155	2.0806	112	Positive	Positive	2.2521	0.9010
81	Negative	Negative	0.7031	2.1240	113	Positive	Positive	2.0730	0.5767
82	Negative	Negative	0.5441	2.0361	114	Positive	Positive	2.2517	0.7204
83	Negative	Negative	0.9665	1.9088	115	Positive	Positive	2.1161	0.7275
84	Negative	Negative	0.7466	2.0016	116	Positive	Positive	3.3797	2.2441
85	Negative	Negative	0.5950	1.7890	117	Positive	Positive	2.1528	0.9966
86	Negative	Negative	0.8243	1.7350	118	Positive	Positive	2.2350	0.6900
87	Negative	Negative	0.7022	1.8702	119	Positive	Positive	2.3530	0.7383
88	Negative	Negative	0.6387	2.2102	120	Positive	Positive	2.3606	0.8709
89	Positive	Positive	1.9220	0.8354	121	Positive	Positive	1.9114	0.8575
90	Positive	Positive	2.2962	2.2040	122	Positive	positive	2.0663	0.9400
91	Positive	Positive	3.3931	2.9133	123	Positive	Positive	2.1872	0.7300
92	Positive	Positive	1.7020	1.1363	124	Positive	Positive	2.5551	1.2442
93	Positive	positive	2.2018	1.4818	125	Positive	Positive	2.7751	1.1445
94	positive	Positive	1.9611	1.2487	126	Positive	Positive	2.3620	0.9722
95	Positive	Positive	3.8946	3.1912	127	Positive	Positive	1.9574	0.7407
96	Positive	Positive	1.6926	0.4892					
97	Positive	Positive	1.6115	0.5010					
98	Positive	Positive	1.6557	0.4197					
99	Positive	Positive	2.0984	0.8972					
100	Positive	Positive	2.4743	1.5703					
101	Positive	Positive	1.7862	0.9653					
102	Positive	Positive	1.4503	0.9498					
103	Positive.	Positive	2.2970	0.8518					
104	Positive	Positive	2.3075	0.7242					
105	Positive	Positive	1.4227	0.8649					
106	Positive	Positive	2.4659	0.9935					

8/23

FIG. 6



9/23

FIG. 7A

EXAMPLE 1 VALIDATION RESULTS TABLE

Sample Index	Actual Class	Calculated Class	Distance to Negative	Distance to Positive	Sample Index	Actual Class	Calculated Class	Distance to Negative	Distance to Positive
1	Positive	Positive	3.5082	2.3019	2	Negative	Negative	1.2400	2.3332
3	Positive	Positive	2.1924	1.1372	4	Negative	Negative	1.4383	3.0949
5	Positive	Positive	3.0470	1.7296	6	Negative	Negative	1.2284	2.9079
7	Negative	Negative	0.6421	1.6213	8	Positive	Positive	2.7582	1.5287
9	Negative	Negative	0.9889	1.6983	10	Positive	Positive	2.1312	1.1608
11	Positive	Positive	3.1882	2.6585	12	Positive	Positive	3.5244	2.3825
13	Negative	Negative	1.1107	1.5189	14	Negative	Negative	1.8006	2.7003
15	Negative	Negative	1.0342	1.6337	16	Negative	Negative	1.3039	2.9658
17	Negative	Negative	0.7268	2.0708	18	Negative	Negative	0.7942	2.4927
19	Negative	Negative	0.5754	1.7993	20	Negative	Negative	0.8507	2.3928
21	Negative	Negative	1.0327	2.1462	22	Negative	Negative	0.8940	1.8257
23	Negative	Negative	0.8728	1.6968	24	Negative	Negative	1.1563	2.6630
25	Negative	Negative	0.5741	1.8714	26	Negative	Negative	0.8330	1.9455
27	Negative	Negative	0.5863	1.8091	28	Negative	Negative	0.7366	2.2724
29	Positive	Positive	2.9832	1.7446	30	Negative	Negative	0.7733	2.3764
31	Positive	Positive	2.7804	1.4467	32	Negative	Negative	0.9039	2.4166
33	Negative	Negative	0.7466	1.6162	34	Negative	Negative	1.1627	2.6755
35	Negative	Negative	0.7433	1.6506	36	Negative	Negative	0.7595	1.9008
37	Negative	Negative	0.7199	1.6782	38	Negative	Negative	0.7604	2.1766
39	Positive	Positive	2.9490	1.6552	40	Negative	Negative	0.5268	2.1890
41	Positive	Positive	2.2614	0.9470	42	Negative	Negative	0.9996	2.4177
43	Positive	Positive	2.8809	1.7337	44	Negative	Negative	9.7966	10.5668
45	Positive	Positive	2.5892	1.0581	46	Negative	Negative	1.1302	2.7211
47	Positive	Positive	3.7227	2.2994	48	Negative	Negative	1.4172	3.0395
49	Positive	Positive	2.5579	1.2121	50	Negative	Negative	1.2156	2.9043
51	Negative	Negative	1.3664	2.9653	52	Negative	Negative	1.2373	2.8794
53	Negative	Negative	2.6234	3.7285	54	Negative	Negative	1.2913	2.9506
55	Negative	Negative	1.4738	3.1055	56	Negative	Negative	1.0769	2.7398
57	Negative	Negative	0.7448	2.2940	58	Negative	Negative	0.9805	2.3530
59	Negative	Negative	1.2918	2.9177	60	Negative	Negative	1.3000	2.9161
61	Negative	Negative	1.3960	3.0741	62	Negative	Negative	0.6882	1.7908
63	Positive	Positive	2.6188	1.3658	64	Negative	Negative	1.2183	2.8400
65	Negative	Negative	0.5263	1.9742	66	Negative	Negative	0.7831	2.1766
67	Negative	Negative	1.2374	2.7730	68	Positive	Positive	3.6616	2.3504
69	Negative	Negative	0.8134	2.3941	70	Positive	Positive	2.5722	1.2911
71	Negative	Negative	0.7686	2.3918	72	Positive	Positive	3.0629	1.5557

10/23


FIG. 7B

EXAMPLE 1 VALIDATION RESULTS TABLE

Sample Index	Actual Class	Calculated Class	Distance to Negative	Distance to Positive	Sample Index	Actual Class	Calculated Class	Distance to Negative	Distance to Positive
73	Negative	Negative	0.6773	1.8953	74	Positive	Positive	2.4086	1.2736
75	Negative	Negative	1.5635	2.5540	76	Positive	Positive	2.2698	1.1630
77	Negative	Negative	0.9426	2.5927	78	Positive	Positive	2.5289	1.1963
79	Negative	Negative	1.6345	2.9514	80	Positive	Positive	2.4924	1.2331
81	Negative	Negative	0.7612	2.1395	82	Positive	Positive	2.7077	1.6358
83	Negative	Negative	0.6804	1.9048	84	Positive	Positive	2.7940	1.1426
85	Positive	Positive	2.6181	1.4452					

11/23

FIG. 8



12/23

FIG. 9





FIG. 10




14/23

FIG. 11

EXAMPLE 3 CALIBRATION RESULTS TABLE – SCRAPIE

Sample Number	Actual Class	Calculated	Distance to Negative	Distance to Positive
1	Positive	Positive	1.8588	0.8886
2	negative	negative	0.9306	2.3064
3	negative	negative	0.5676	1.7561
4	negative	negative	0.8339	2.1601
5	negative	negative	0.9887	2.055
6	negative	negative	1.3259	2.2305
7	negative	negative	1.1108	1.9913
8	Positive	Positive	1.4288	0.6562
9	negative	negative	0.8941	1.4485
10	negative	negative	0.9908	1.9755
11	negative	negative	1.4161	2.1912
12	Positive	Positive	2.0709	1.3431
13	negative	negative	0.6423	1.2766
14	negative	negative	0.7067	1.0519
15	negative	negative	0.5449	1.5285
16	negative	negative	0.7981	1.6764
17	negative	negative	1.1144	1.8372
18	negative	negative	1.5611	2.2564
19	negative	negative	0.9667	1.5489
20	negative	negative	1.0083	1.616
21	negative	negative	0.7992	1.5822
22	Positive	Positive	1.6621	1.1461
23	negative	negative	0.7418	1.2417
24	negative	negative	0.7621	1.6655
25	Positive	Positive	1.3257	0.9086
26	Positive	Positive	1.6019	1.6221
27	Positive	Positive	2.1476	0.9236
28	Positive	Positive	1.6609	0.6053
29	Positive	Positive	2.2007	1.4753
30	Positive	Positive	1.7917	0.6345

FIG. 12



16/23


FIG. 13

VALIDATION TEST RESULTS – SCRAPIE

Sample Index	Actual Class	Calculated Class	Distance to Positive	Distance to negative
1	Positive	Positive	0.830	1.1996
2	Positive	Positive	0.935	1.3143
3	Positive	Positive	0.823	1.4005
4	negative	negative	1.679	1.1633
5	negative	negative	2.093	1.694
6	negative	negative	1.401	1.0633
7	negative	negative	1.161	0.953
8	negative	negative	1.467	1.1644
9	negative	negative	1.777	1.5404
10	negative	negative	1.674	1.1015
11	negative	negative	1.851	1.1216
12	negative	negative	1.321	1.094
13	negative	negative	2.217	1.2391
14	Positive	Positive	1.000	1.4145
15	Positive	Positive	1.243	1.422

17/23

FIG. 14




18/23

FIG. 15

SHEEP WHOLE BLOOD

Sample Number	Actual Class	Calculated Class	Distance	Next Class	Next Distance	Distance to Negative	Distance to Positive
1	NEGATIVE	NEGATIVE	0.9259	POSITIVE	5.1759	0.9259	5.1759
2	POSITIVE	POSITIVE	0.8165	NEGATIVE	1.4397	1.4397	0.8165
3	POSITIVE	POSITIVE	0.8165	NEGATIVE	1.5625	1.5625	0.8165
4	POSITIVE	POSITIVE	0.8165	NEGATIVE	4.7251	4.7251	0.8165
5	NEGATIVE	NEGATIVE	0.9259	POSITIVE	8.8615	0.9259	8.8615
6	NEGATIVE	NEGATIVE	0.9259	POSITIVE	5.7122	0.9259	5.7122
7	NEGATIVE	NEGATIVE	0.9258	POSITIVE	1.3303	0.9258	1.3303
8	NEGATIVE	NEGATIVE	0.9258	POSITIVE	1.9879	0.9258	1.9879
9	NEGATIVE	NEGATIVE	0.9258	POSITIVE	5.2486	0.9258	5.2486
10	NEGATIVE	NEGATIVE	0.9257	POSITIVE	2.6318	0.9257	2.6318
11	NEGATIVE	NEGATIVE	0.5929	POSITIVE	3.1081	0.5929	3.1081
12	POSITIVE	POSITIVE	0.2218	NEGATIVE	2.5302	2.5302	0.2218

FIG. 16



20/23

FIG. 17

SHEEP SERUM PATENT

Sample Number	Actual Class	Calculated Class	Distance	Next Class	Next Distance	Distance to Negative	Distance to Positive
1	NEGATIVE	NEGATIVE	0.9403	POSITIVE	3.4690	0.9403	3.4690
2	POSITIVE	POSITIVE	0.9484	NEGATIVE	2.3916	2.3916	0.9484
3	POSITIVE	POSITIVE	0.9493	NEGATIVE	1.2323	1.2323	0.9493
4	POSITIVE	POSITIVE	0.9487	NEGATIVE	1.3000	1.3000	0.9487
5	POSITIVE	POSITIVE	0.9487	NEGATIVE	1.7450	1.7450	0.9487
6	NEGATIVE	NEGATIVE	1.0232	POSITIVE	8.3969	1.0232	8.3969
7	NEGATIVE	NEGATIVE	0.9523	POSITIVE	4.1197	0.9523	4.1197
8	NEGATIVE	NEGATIVE	1.0081	POSITIVE	1.6274	1.0081	1.6274
9	NEGATIVE	NEGATIVE	0.8975	POSITIVE	2.2837	0.8975	2.2837
10	NEGATIVE	NEGATIVE	1.0104	POSITIVE	3.8308	1.0104	3.8308
11	NEGATIVE	NEGATIVE	0.9159	POSITIVE	2.7603	0.9159	2.7603
12	NEGATIVE	NEGATIVE	0.9953	POSITIVE	1.8128	0.9953	1.8128
13	NEGATIVE	NEGATIVE	0.9654	POSITIVE	3.1815	0.9654	3.1815
14	POSITIVE	POSITIVE	0.9488	NEGATIVE	1.6348	1.6348	0.9488
15	POSITIVE	POSITIVE	0.9488	NEGATIVE	2.2146	2.2146	0.9488
16	POSITIVE	POSITIVE	0.9487	NEGATIVE	1.3196	1.3196	0.9487
17	NEGATIVE	NEGATIVE	1.0168	POSITIVE	10.6559	1.0168	10.6559
18	NEGATIVE	NEGATIVE	0.9430	POSITIVE	4.7479	0.9430	4.7479
19	NEGATIVE	NEGATIVE	1.0070	POSITIVE	2.8895	1.0070	2.8895
20	NEGATIVE	NEGATIVE	1.0221	POSITIVE	2.9706	1.0221	2.9706
21	NEGATIVE	NEGATIVE	0.9808	POSITIVE	1.8942	0.9808	1.8942
22	NEGATIVE	NEGATIVE	0.9388	POSITIVE	2.2425	0.9388	2.2425
23	NEGATIVE	NEGATIVE	1.0189	POSITIVE	1.2239	1.0189	1.2239
24	NEGATIVE	NEGATIVE	0.9937	POSITIVE	5.4163	0.9937	5.4163
25	POSITIVE	POSITIVE	0.9482	NEGATIVE	1.3000	1.3000	0.9482
26	POSITIVE	POSITIVE	0.9486	NEGATIVE	2.1448	2.1448	0.9486
27	POSITIVE	POSITIVE	0.9487	NEGATIVE	1.5835	1.5835	0.9487
28	NEGATIVE	NEGATIVE	0.9796	POSITIVE	7.9655	0.9796	7.9655
29	NEGATIVE	NEGATIVE	0.9156	POSITIVE	5.2526	0.9156	5.2526
30	NEGATIVE	NEGATIVE	0.9063	POSITIVE	1.3872	0.9063	1.3872
31	NEGATIVE	NEGATIVE	1.0005	POSITIVE	2.7041	1.0005	2.7041
32	NEGATIVE	NEGATIVE	0.9753	POSITIVE	2.2191	0.9753	2.2191
33	NEGATIVE	NEGATIVE	0.9716	POSITIVE	2.3063	0.9716	2.3063
34	NEGATIVE	NEGATIVE	0.9984	POSITIVE	1.3904	0.9984	1.3904
35	POSITIVE	POSITIVE	0.6561	NEGATIVE	1.3452	1.3452	0.6561


21/23

FIG. 18

Scrapie – Serum Sample Scores

Sample Number	Distance to Negative	Distance to Positive	Score
1	0.8822	1.7715	-0.8893
2	1.2768	0.9925	0.2843
3	1.3689	0.9932	0.3757
4	1.4333	0.9934	0.4399
5	1.5194	0.9893	0.5301
6	1.0571	3.7293	-2.6722
7	0.993	2.0862	-1.0932
8	1.0251	1.3151	-0.29
9	1.0175	1.3344	-0.3169
10	0.9439	1.2529	-0.309
11	1.044	1.5522	-0.5082
12	0.892	1.6811	-0.7891
13	0.9163	2.1196	-1.2033
14	1.7724	0.9972	0.7752
15	1.4607	0.9631	0.4976
16	1.0592	0.9945	0.0647
17	1.4367	0.9262	0.5105
18	0.971	3.2062	-2.2352
19	1.0194	1.9678	-0.9484
20	1.1064	1.5049	-0.3985
21	0.9158	1.479	-0.5632
22	1.0108	1.5059	-0.4951
23	0.9008	1.7008	-0.8
24	0.9357	1.4245	-0.4888
25	1.0446	1.4702	-0.4256
26	0.9737	2.4454	-1.4717
27	1.6908	0.977	0.7138
28	2.2448	0.9714	1.2734
29	1.153	0.9135	0.2395
30	1.1097	0.9835	0.1262
31	1.177	0.9633	0.2137
32	1.3239	0.9985	0.3254
33	0.948	0.6517	0.2963
34	1.677	0.9941	0.6829
35	1.0311	0.9299	0.1012
36	1.4379	0.9809	0.457
37	1.9556	0.9905	0.9651
38	1.7041	1.0022	0.7019
39	1.8029	0.9995	0.8034
40	1.1631	0.9975	0.1656
41	1.3565	0.9997	0.3568
42	1.0713	2.3827	-1.3114
43	1.0086	1.5585	-0.5499
44	1.404	0.9424	0.4616
45	1.0482	1.8484	-0.8002
46	0.9307	1.8557	-0.925
47	0.9946	1.8624	-0.8678
48	0.8455	1.2993	-0.4538
49	1.3344	1.0043	0.3301
50	1.0278	1.3599	-0.3321
51	0.9626	2.1286	-1.166
52	1.0883	0.996	0.0923
53	0.9602	1.6305	-0.6703
54	2.0941	0.9926	1.1015
55	1.0329	1.555	-0.5221
56	1.0018	1.3792	-0.3774
57	1.0159	1.6215	-0.6056
58	0.8433	1.241	-0.3977
59	1.0119	1.2737	-0.2618
60	0.8601	1.0513	-0.1912
61	1.3516	1.0009	0.3507
62	1.0404	1.8698	-0.8294
63	1.0645	1.4256	-0.3611

FIG. 19



23/23

FIG. 20

SHEEP PLASMA

Sample Number	Actual Class	Calculated	Distance	Next Class	Next Distance	Distance to NEGATIVE	Distance to POSITIVE
		Class					
1	NEGATIVE	NEGATIVE	0.8822	POSITIVE	1.7715	0.8822	1.7715
2	POSITIVE	POSITIVE	0.9925	NEGATIVE	1.2768	1.2768	0.9925
3	POSITIVE	POSITIVE	0.9932	NEGATIVE	1.3689	1.3689	0.9932
4	POSITIVE	POSITIVE	0.9934	NEGATIVE	1.4333	1.4333	0.9934
5	POSITIVE	POSITIVE	0.9893	NEGATIVE	1.5194	1.5194	0.9893
6	NEGATIVE	NEGATIVE	1.0571	POSITIVE	3.7293	1.0571	3.7293
7	NEGATIVE	NEGATIVE	0.9930	POSITIVE	2.0862	0.9930	2.0862
8	NEGATIVE	NEGATIVE	1.0251	POSITIVE	1.3151	1.0251	1.3151
9	NEGATIVE	NEGATIVE	1.0175	POSITIVE	1.3344	1.0175	1.3344
10	NEGATIVE	NEGATIVE	0.9439	POSITIVE	1.2529	0.9439	1.2529
11	NEGATIVE	NEGATIVE	1.0440	POSITIVE	1.5522	1.0440	1.5522
12	NEGATIVE	NEGATIVE	0.8920	POSITIVE	1.6811	0.8920	1.6811
13	NEGATIVE	NEGATIVE	0.9163	POSITIVE	2.1196	0.9163	2.1196
14	POSITIVE	POSITIVE	0.9972	NEGATIVE	1.7724	1.7724	0.9972
15	POSITIVE	POSITIVE	0.9631	NEGATIVE	1.4607	1.4607	0.9631
16	POSITIVE	POSITIVE	0.9945	NEGATIVE	1.0592	1.0592	0.9945
17	POSITIVE	POSITIVE	0.9262	NEGATIVE	1.4367	1.4367	0.9262
18	NEGATIVE	NEGATIVE	0.9710	POSITIVE	3.2062	0.9710	3.2062
19	NEGATIVE	NEGATIVE	1.0194	POSITIVE	1.9678	1.0194	1.9678
20	NEGATIVE	NEGATIVE	1.1064	POSITIVE	1.5049	1.1064	1.5049
21	NEGATIVE	NEGATIVE	0.9158	POSITIVE	1.4790	0.9158	1.4790
22	NEGATIVE	NEGATIVE	1.0108	POSITIVE	1.5059	1.0108	1.5059
23	NEGATIVE	NEGATIVE	0.9008	POSITIVE	1.7008	0.9008	1.7008
24	NEGATIVE	NEGATIVE	0.9357	POSITIVE	1.4245	0.9357	1.4245
25	NEGATIVE	NEGATIVE	1.0446	POSITIVE	1.4702	1.0446	1.4702
26	NEGATIVE	NEGATIVE	0.9737	POSITIVE	2.4454	0.9737	2.4454
27	POSITIVE	POSITIVE	0.9770	NEGATIVE	1.6908	1.6908	0.9770
28	POSITIVE	POSITIVE	0.9714	NEGATIVE	2.2448	2.2448	0.9714
29	POSITIVE	POSITIVE	0.9135	NEGATIVE	1.1530	1.1530	0.9135
30	POSITIVE	POSITIVE	0.9835	NEGATIVE	1.1097	1.1097	0.9835
31	POSITIVE	POSITIVE	0.9633	NEGATIVE	1.1770	1.1770	0.9633
32	POSITIVE	POSITIVE	0.9985	NEGATIVE	1.3239	1.3239	0.9985
33	POSITIVE	POSITIVE	0.6517	NEGATIVE	0.9480	0.9480	0.6517
34	POSITIVE	POSITIVE	0.9941	NEGATIVE	1.6770	1.6770	0.9941
35	POSITIVE	POSITIVE	0.9299	NEGATIVE	1.0311	1.0311	0.9299
36	POSITIVE	POSITIVE	0.9809	NEGATIVE	1.4379	1.4379	0.9809
37	POSITIVE	POSITIVE	0.9905	NEGATIVE	1.9556	1.9556	0.9905
38	POSITIVE	POSITIVE	1.0022	NEGATIVE	1.7041	1.7041	1.0022
39	POSITIVE	POSITIVE	0.9995	NEGATIVE	1.8029	1.8029	0.9995
40	POSITIVE	POSITIVE	0.9975	NEGATIVE	1.1631	1.1631	0.9975
41	POSITIVE	POSITIVE	0.9997	NEGATIVE	1.3565	1.3565	0.9997
42	NEGATIVE	NEGATIVE	1.0713	POSITIVE	2.3827	1.0713	2.3827
43	NEGATIVE	NEGATIVE	1.0086	POSITIVE	1.5585	1.0086	1.5585
44	POSITIVE	POSITIVE	0.9424	NEGATIVE	1.4040	1.4040	0.9424
45	NEGATIVE	NEGATIVE	1.0482	POSITIVE	1.8484	1.0482	1.8484
46	NEGATIVE	NEGATIVE	0.9307	POSITIVE	1.8557	0.9307	1.8557
47	NEGATIVE	NEGATIVE	0.9946	POSITIVE	1.8624	0.9946	1.8624
48	NEGATIVE	NEGATIVE	0.8455	POSITIVE	1.2993	0.8455	1.2993
49	POSITIVE	POSITIVE	1.0043	NEGATIVE	1.3344	1.3344	1.0043
50	NEGATIVE	NEGATIVE	1.0278	POSITIVE	1.3599	1.0278	1.3599
51	NEGATIVE	NEGATIVE	0.9696	POSITIVE	2.1286	0.9696	2.1286
52	POSITIVE	POSITIVE	0.9960	NEGATIVE	1.0883	1.0883	0.9960
53	NEGATIVE	NEGATIVE	0.9602	POSITIVE	1.6305	0.9602	1.6305
54	POSITIVE	POSITIVE	0.9926	NEGATIVE	2.0941	2.0941	0.9926
55	NEGATIVE	NEGATIVE	1.0329	POSITIVE	1.5550	1.0329	1.5550
56	NEGATIVE	NEGATIVE	1.0018	POSITIVE	1.3792	1.0018	1.3792
57	NEGATIVE	NEGATIVE	1.0159	POSITIVE	1.6215	1.0159	1.6215
58	NEGATIVE	NEGATIVE	0.8433	POSITIVE	1.2410	0.8433	1.2410
59	NEGATIVE	NEGATIVE	1.0119	POSITIVE	1.2737	1.0119	1.2737
60	NEGATIVE	NEGATIVE	0.8601	POSITIVE	1.0513	0.8601	1.0513
61	POSITIVE	POSITIVE	1.0009	NEGATIVE	1.3516	1.3516	1.0009
62	NEGATIVE	NEGATIVE	1.0404	POSITIVE	1.8698	1.0404	1.8698
63	NEGATIVE	NEGATIVE	1.0645	POSITIVE	1.4256	1.0645	1.4256

INTERNATIONAL SEARCH REPORT

international application no.
PCT/US04/35550

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(7) : G01N 33/00, 21/00, 33/48, 33/53
 US CL : 436/86, 164, 63, 811
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 436/86, 164, 63, 811

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 EMBASE, MEDLINE, BIOSIS, SCISEARCH, CAPLUS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	WO 00/72007 (ROBERT-KOCH-INSTITUT) 30 November 2000, 30.11.00), see entire document.	1, 2, 4-11, 13-22 ----- 3, 12, 23-29
X,P	US 6,777,241 B1 (NAUMANN et al.) 17 August 2004 (17.08.04), see entire document.	1, 2, 4-11, 13-22 ----- 3, 12, 23-29
A	Schmitt et al., Identification of Scrapie Infection from Blood Serum by Fourier Transform Infrared Spectrometry, Anal. Chem. 2002, 74, 3865-3868. See entire document.	1-29
A	Kneipp et al., Molecular Changes of Preclinical Scrapie Can Be Detected by Infrared Spectroscopy, The Journal of Neuroscience, April 15, 2002, 22(8): 2989-2997. See entire document.	1-29
A	Kneipp et al., In situ spectroscopic investigation of transmissible spongiform encephalopathies: Application of Fourier-transform infrared spectroscopy to a scrapie-hamster model. Proceedings of SPIE Vol. 4614 (2002), pages 12-19. See entire document.	1-29

Further documents are listed in the continuation of Box C. See patent family annex.

<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>
---	---

Date of the actual completion of the international search 14 March 2005 (14.03.2005)	Date of mailing of the international search report 04 APR 2005
---	--

Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	Authorized officer <i>Maria J. Wab</i> Gary Counts Telephone No. (703) 308-0196
---	---

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US04/35550

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6,157,041 A (THOMAS et al.) 05 December 2000 (05.12.00), see entire document.	1-29